

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 3354273 T3**

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: **A 61 K 38/04 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2021-06-28**
- (80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2021-03-24**
- (86) Europæisk ansøgning nr.: **17202836.7**
- (86) Europæisk indleveringsdag: **2006-07-10**
- (87) Den europæiske ansøgnings publiceringsdag: **2018-08-01**
- (30) Prioritet: **2005-07-08 US 697779 P** **2005-12-09 US 748850 P**
- (62) Stamansøgningsnr: **12188784.8**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL
PL PT RO SE SI SK TR**
- (73) Patenthaver: **IPSEN PHARMA, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, Frankrig**
- (72) Opfinder: **Dong, Zheng Xin, 66 Fairview Street, Holliston, MA 01746, USA
MOREAU, Jacques-Pierre, 159 Westboro Road, Upton, MA 01568, USA**
- (74) Fuldmægtig i Danmark: **NORDIC PATENT SERVICE A/S, Bredgade 30, 1260 København K, Danmark**
- (54) Benævnelse: **MELANOCORTINRECEPTORLIGANDER**
- (56) Fremdragne publikationer:
WO-A-2005/000339
**HASKELL-LUEVANO C ET AL: "BIOLOGICAL AND CONFORMATIONAL EXAMINATION OF STEREOCHEMICAL
MODIFICATIONS USING THE TEMPLATE MELANOTROPIN PEPTIDE, AC-NLE-CÄASP-HIS-PHE-ARG-TRP-ALA-
LYSÜ-NH2, ON HUMAN MELANOCORTIN RECEPTORS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN
CHEMICAL SOCIETY, WASHINGTON, US, vol. 40, no. 11, 1 January 1997 (1997-01-01), pages 1738-1748,
XP002159224, ISSN: 0022-2623**

Description

BACKGROUND OF THE INVENTION

[0001] The present invention is directed to medical use of peptides which are ligands of one or more of the melanocortin receptors (MC-R) or the pharmaceutically-acceptable salts thereof, including medical use of such peptides to treat mammals, and to medical use of useful pharmaceutical compositions comprising said peptides.

[0002] Melanocortins are a family of regulatory peptides which are formed by post-translational processing of pro-hormone pro-opiomelanocortin (POMC; 131 amino acids in length). POMC is processed into three classes of hormones; the melanocortins, adrenocorticotropin hormone, and various endorphins (e.g. lipotropin) (Cone, et al., Recent Prog. Horm. Res., 51:287-317, (1996); Cone et al., Ann. N.Y. Acad. Sci., 31:342-363, (1993)).

[0003] Melanocortins have been found in a wide variety of normal human tissues including the brain, adrenal, skin, testis, spleen, kidney, ovary, lung, thyroid, liver, colon, small intestine and pancreas (Tatro, J. B. et al., Endocrinol. 121:1900-1907 (1987); Mountjoy, K. G. et al., Science 257:1248-1251 (1992); Chhajlani, V. et al., FEBS Lett. 309:417-420 (1992); Gantz, I. et al. J. Biol. Chem. 268:8246-8250 (1993) and Gantz, I. et al., J. Biol. Chem. 268:15174-15179 (1993)).

[0004] Melanocortin peptides have been shown to exhibit a wide variety of physiological activities including the control of behavior and memory, affecting neurotrophic and antipyretic properties, as well as affecting the modulation of the immune system. Aside from their well known effects on adrenal cortical functions (adrenocorticotrophic hormone, ACTH) and on melanocytes (melanocyte stimulating hormone, MSH), melanocortins have also been shown to control the cardiovascular system, analgesia, thermoregulation and the release of other neurohumoral agents including prolactin, luteinizing hormone and biogenic amines (De Wied, D. et al., Methods Achiev. Exp. Pathol. 15:167-199 (1991); De Wied, D. et al., Physiol. Rev. 62:977-1059 (1982); Guber, K.A. et al., Am. J. Physiol. 257:R681-R694 (1989); Walker J.M. et al., Science 210:1247-1249 (1980); Murphy, M. T. et al., Science 221:192-193 (1983); Ellerkmann, E. et al., Endocrinol. 130:133-138 (1992) and Versteeg, D. H. G. et al., Life Sci. 38:835-840 (1986)).

[0005] It has also been shown that binding sites for melanocortins are distributed in many different tissue types including lachrymal and submandibular glands, pancreas, adipose, bladder, duodenum, spleen, brain and gonadal tissues as well as malignant melanoma tumors. Five melanocortin receptors (MC-R) have been characterized to date. These include melanocyte-specific receptor (MC1-R), corticoadrenal-specific ACTH receptor (MC2-R), melanocortin-3 (MC3-R), melanocortin-4 (MC4-R) and melanocortin-5 receptor (MC5-R). All of the melanocortin receptors respond to the peptide hormone class of melanocyte stimulating hormones (MSH) (Cone, R. D. et al., Ann. N.Y. Acad. Sci., 680:342-363 (1993); Cone, R. D. et al., Recent Prog. Horm. Res., 51:287-318 (1996)).

[0006] MC1-R, known in the art as Melanocyte Stimulating Hormone Receptor (MSH-R), Melanotropin Receptor or Melanocortin-1 Receptor, is a 315 amino acid transmembrane protein belonging to the family of G-Protein coupled receptors. MC1-R is a receptor for both MSH and ACTH. The activity of MC1-R is mediated by G-proteins which activate adenylate cyclase. MC1-R receptors are found in melanocytes and corticoadrenal tissue as well as various other tissues such as adrenal gland, leukocytes, lung, lymph node, ovary, testis, pituitary, placenta, spleen and uterus. MC2-R, also called Adrenocorticotrophic hormone receptor (ACTH-R), is a 297 amino acid transmembrane protein found in melanocytes and the corticoadrenal tissue. MC2-R mediates the corticotrophic effect of ACTH. In humans, MC3-R is a 360 AA protein found in brain tissue; in mice and rats MC3-R is a 323 AA protein. MC4-R is a 332 amino acid transmembrane protein which is also expressed in brain as well as placental and gut tissues. MC5-R is a 325 amino acid transmembrane protein expressed in the adrenals, stomach, lung and spleen and very low levels in the brain. MC5-R is also expressed in the three layers of adrenal cortex, predominantly in the aldosterone-producing zona glomerulosa cells.

[0007] The five known melanocortin receptors differ, however, in their functions. For example, MC1-R is a G-protein coupled receptor that regulates pigmentation in response to α -MSH, a potent agonist of MC1-R. Agonism of the MC1-R receptor results in stimulation of the melanocytes which causes eumelanin and increases the risk for cancer of the skin. Agonism of MC1-R can also have neurological effects. Stimulation of MC2-R activity can result in carcinoma of adrenal tissue. Recent pharmacological confirmation has established that central MC4-R receptors are the prime mediators of the anorexic and orexigenic effects reported for melanocortin agonists and antagonists, respectively. The effects of agonism of the MC3-R and MC5-R are not yet known.

[0008] There has been great interest in melanocortin (MC-R) receptors as targets for the design of novel therapeutics to treat disorders of body weight such as obesity and cachexia. Both genetic and pharmacological evidence points toward central MC4-R receptors as the principal target (Giraud, S. Q. et al., Brain Res., 809:302-306 (1998); Farooqi, I. S. et al., NE J Med., 348:1085-1095 (2003); MacNeil, D. J. et al., Eu. J. Pharm., 44:141-157 (2002); MacNeil, D. J. et al., Eu. J. Pharm., 450:93-109 (2002); Kask, A. et al., NeuroReport, 10:707-711 (1999)). The current progress with receptor-selective agonists and antagonists evidences the therapeutic potential of melanocortin receptor activation, particularly MC4-R.

[0009] Agonist, antagonist or other ligand compounds activating one or more melanocortin receptor would be useful for treating a wide variety of indications in a subject in need thereof or at risk thereof including acute and chronic

inflammatory diseases such as general inflammation (U.S. Patent No. 6,613,874; Catania, A. et al., Pharm. Rev., 56:1-29 (2004)), inflammatory bowel disease (U.S. Patent No. 6,713,487; Catania, A. et al., Pharm. Rev., 56:1-29 (2004)), brain inflammation (Catania, A. et al., Pharm. Rev., 56:1-29 (2004)), sepsis (U.S. Patent No. 6,613,874; U.S. Patent No. 6,713,487; Catania, A. et al., Pharm. Rev., 56:1-29 (2004)) and septic shock (U.S. Patent No. 6,613,874; Catania, A. et al., Pharm. Rev., 56:1-29 (2004)); diseases with an autoimmune component such as rheumatoid arthritis (U.S. Patent No. 6,713,487; Catania, A. et al., Pharm. Rev., 56:1-29 (2004)), gouty arthritis (Catania, A. et al., Pharm. Rev., 56:1-29 (2004)), Getting, S. J. et al., Curr. Opin. Investig. Drugs, 2:1064-1069 (2001)), and multiple sclerosis ((U.S. Patent No. 6,713,487); metabolic diseases and medical conditions accompanied by weight gain such as obesity (U.S. Patent No. 6,613,874; U.S. Patent No. 6,600,015; Fehm, H. L. et al., J. Clin. Endo. & Metab., 86:1144-1148 (2001); Hansen, M. J. et al., Brain Res., 1039:137-145 (2005); Ye, Z. et al., Peptides, 26:2017-2025 (2005); Farooqi, I. S. et al., NE J Med., 348:1085-1095 (2003); MacNeil, D. J. et al., Eu. J. Pharm., 44:141-157 (2002); MacNeil, D. J. et al., Eu. J. Pharm., 450:93-109 (2002); Kask, A. et al., NeuroReport, 10:707-711 (1999); Schwartz, M. W., J. Clin. Invest., 108:963-964 (2001), Gura, T., Science, 287:1738-1740 (2000), Raffin-Sanson, M. L., Eu. J. Endo., 144:207-208 (2001), Hamilton, B. S. et al., Obesity Res. 10:182-187 (2002)), feeding disorders (U.S. Patent No. 6,720,324; Fehm, H. L. et al., J. Clin. Endo. & Metab., 86:1144-1148 (2001); Pontillo, J. et al., Bioorganic & Med. Chem. Ltrs., 15:2541-2546 (2005)) and Prader-Willi Syndrome (GE, Y. et al., Brain Research, 957:42-45 (2002)); metabolic diseases and medical conditions accompanied by weight loss such as anorexia (U.S. Patent No. 6,613,874; Wisse, B. R. et al., Endo., 142:3292-3301 (2001)), bulimia (U.S. Patent No. 6,720,324), AIDS wasting (Marsilje, T. H. et al., Bioorg. Med. Chem. Lett., 14:3721-3725 (2004); Markison, S. et al., Endocrinology, 146:2766-2773 (2005)), cachexia (U.S. Patent No. 6,613,874; Lechan, R. M. et al., Endo., 142:3288-3291 (2001); Pontillo, J. et al., Bioorganic & Med. Chem. Ltrs., 15:2541-2546 (2005)), cancer cachexia (U.S. Patent No. 6,639,123) and wasting in frail elderly (U.S. Patent No. 6,639,123); diabetes (U.S. Patent No. 6,713,487) and diabetological related conditions and complications of diabetes such as retinopathy (U.S. Patent No. 6,525,019); neoplastic proliferation (U.S. Patent No. 6,713,487) such as skin cancer (Sturm, R.A., Melanoma Res., 12:405-416 (2002); Bastiens, M. T. et al., Am. J. Hum. Genet., 68:884-894 (2001)), and prostate cancer (Luscombe, C. J. et al., British J. Cancer, 85:1504-1509 (2001); reproductive or sexual medical conditions such as endometriosis (U.S. Patent No. 6,713,487) and uterine bleeding in women (U.S. Patent No. 6,613,874), sexual dysfunction (U.S. Patent No. 6,720,324; Van der Ploeg, L. H. T. et al., PNAS, 99:11381-11386 (2002), Molinoff, P. B. et al., Ann. N.Y. Acad. Sci., 994:96-102 (2003), Hopps, C. V. et al., BJU International, 92:534-538 (2003)), erectile dysfunction ((U.S. Patent No. 6,613,874; Diamond, L. E. et al., Urology, 65:755-759 (2005), Wessells, H. et al., Int. J. Impotence Res., 12:S74-S79 (2000), Andersson K-E. et al., Int. J. Impotence Res., 14:S82-S92 (2002), Bertolini, A. et al., Sexual Behavior: Pharmacology and Biochemistry, Raven Press, NY, p247-257 (1975); Wessells, H. et al., Neuroscience, 118:755-762 (2003), Wessells, H. et al., Urology, 56:641-646 (2000), Shadiack, A. M. et al., Society for Neuroscience Abstract, (2003); Wessells, H. et al., J. Urology, 160:389-393 (1998), Rosen, R. C. et al., Int. J. Impotence Res., 16:135-142 (2004), Wessells, H. et al., Peptides, 26:1972-1977 (2005)) and decreased sexual response in females (U.S. Patent No. 6,713,487; Fourcroy, J. L., Drugs, 63:1445-1457 (2003)); diseases or conditions resulting from treatment or insult to the organism such as organ transplant rejection (U.S. Patent No. 6,713,487; Catania, A. et al., Pharm. Rev., 56:1-29 (2004)), ischemia and reperfusion injury (Mioni, C. et al., Eu. J. Pharm., 477:227-234 (2003); Catania, A. et al., Pharm. Rev., 56:1-29 (2004)), treatment of spinal cord injury and to accelerate wound healing (Sharma H. S. et al., Acta. Neurochir. Suppl., 86:399-405 (2003); Sharma H.S., Ann. N.Y. Acad. Sci. 1053: 407-421 (2005); U.S. Patent No. 6,525,019), as well as weight loss caused by chemotherapy, radiation therapy, temporary or permanent immobilization (Harris, R. B. et al., Physiol. Behav., 73:599-608 (2001)) or dialysis; cardiovascular diseases or conditions such as hemorrhagic shock (Catania, A. et al., Pharm. Rev., 56:1-29 (2004)), cardiogenic shock (U.S. Patent No. 6,613,874), hypovolemic shock (U.S. Patent No. 6,613,874), cardiovascular disorders (U.S. Patent No. 6,613,874) and cardiac cachexia (Markison, S. et al., Endocrinology, 146:2766-2773 (2005); pulmonary diseases or conditions such as acute respiratory distress syndrome (U.S. Patent No. 6,350,430; Catania, A. et al., Pharm. Rev., 56:1-29 (2004)), chronic obstructive pulmonary disease (U.S. Patent No. 6,713,487), asthma (U.S. Patent No. 6,713,487) and pulmonary fibrosis; to enhance immune tolerance (Luger, T. A. et al., Pathobiology, 67:318-321 (1999)) and to combat assaults to the immune system such as those associated with certain allergies (U.S. Patent No. 6,713,487) or organ transplant rejection (U.S. Patent No. 6,713,487; Catania, A. et al., Pharm. Rev., 56:1-29 (2004)); treatment of dermatological diseases and conditions such as psoriasis (U.S. Patent No. 6,713,487), skin pigmentation depletion (U.S. Patent No. 6,713,487; Ye, Z. et al., Peptides, 26:2017-2025 (2005)), acne (Hatta, N. et al., J. Invest. Dermatol., 116:564-570 (2001); Bohm, M. et al., J. Invest. Dermatol., 118:533-539 (2002)), keloid formation (U.S. Patent No. 6,525,019) and skin cancer (Sturm, R.A., Melanoma Res., 12:405-416 (2002); Bastiens, M. T. et al., Am. J. Hum. Genet., 68:884-894 (2001)); behavioral, central nervous system or neuronal conditions and disorders such as anxiety (U.S. Patent No. 6,720,324; Pontillo, J. et al., Bioorganic & Med. Chem. Ltrs., 15:2541-2546 (2005)), depression (Chaki, S. et al., Peptides, 26:1952-1964 (2005), Bednarek, M. A. et al., Expert Opinion Ther. Patents, 14:327-336 (2004); U.S. Patent No. 6,720,324), memory and memory dysfunction (U.S. Patent No. 6,613,874; Voisey, J. et al., Curr. Drug Targets, 4:586-597 (2003)), modulating pain perception (U.S. Patent No. 6,613,874; Bertolini, A. et al., J. Endocrinol. Invest., 4:241-251 (1981); Vrinten, D. et al., J. Neuroscience,

20:8131-8137 (2000)) and treating neuropathic pain (Pontillo, J. et al., Bioorganic & Med. Chem. Ltrs., 15:2541-2546 (2005)); conditions and diseases associated with alcohol consumption, alcohol abuse and/or alcoholism (WO 05/060985; Navarro, M. et al., Alcohol Clin. Exp. Res., 29:949-957 (2005)); and renal conditions or diseases such as the treatment of renal cachexia (Markison, S. et al., Endocrinology, 146:2766-2773 (2005)) or natriuresis (U.S. Patent No. 6,613,874).

5 **[0010]** Ligand compounds activating one or more melanocortin receptor would be useful for modulating a wide variety of normalizing or homeostatic activities in a subject in need thereof including thyroxine release (U.S. Patent No. 6,613,874), aldosterone synthesis and release (U.S. Patent No. 6,613,874), body temperature (U.S. Patent No. 6,613,874), blood pressure (U.S. Patent No. 6,613,874), heart rate (U.S. Patent No. 6,613,874), vascular tone (U.S. Patent No. 6,613,874), brain blood flow (U.S. Patent No. 6,613,874), blood glucose levels (U.S. Patent No. 6,613,874), bone metabolism, bone
10 formation or development (Dumont, L. M. et al., Peptides, 26:1929-1935 (2005), ovarian weight (U.S. Patent No. 6,613,874), placental development (U.S. Patent No. 6,613,874), prolactin and FSH secretion (U.S. Patent No. 6,613,874), intrauterine fetal growth (U.S. Patent No. 6,613,874), parturition (U.S. Patent No. 6,613,874), spermatogenesis (U.S. Patent No. 6,613,874), sebum and pheromone secretion (U.S. Patent No. 6,613,874), neuroprotection (U.S. Patent No. 6,639,123) and nerve growth (U.S. Patent No. 6,613,874) as well as modulating motivation (U.S. Patent No. 6,613,874),
15 learning (U.S. Patent No. 6,613,874) and other behaviors (U.S. Patent No. 6,613,874).

[0011] It is, therefore, an objective of the present invention to provide ligands for the melanocortin receptors which exhibit greater stability and selectivity for melanocortin receptors than native melanocortin receptor ligands.

SUMMARY OF THE INVENTION

20 **[0012]** In one aspect, the invention provides a compound which is Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂ (SEQ ID NO: 50) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the compound and a pharmaceutically acceptable carrier or diluent, for use in therapy.

25 **[0013]** The invention also provides use of a compound for the manufacture of a medicament for the treatment of a metabolic disease or medical condition accompanied by weight gain, wherein said disease or condition is selected from the group consisting of obesity, feeding disorders and Prader-Willi Syndrome, and wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂ (SEQ ID NO: 50) or a pharmaceutically acceptable salt thereof.

[0014] Further aspects of the invention are set out in the claims.

[0015] Also described herein is a compound according formula (I):

30 (R²R³)-A¹-c(A²-A³-A⁴-A⁵-A⁶-A⁷-A⁸-A⁹)-A¹⁰-R¹
wherein:

A¹ is Acc, HN-(CH₂)_m-C(O), L- or D-amino acid, or deleted;

A² is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp, or Glu;

35 A³ is Gly, Ala, β-Ala, Gaba, Aib, D-amino acid, or deleted;

A⁴ is His, 2-Pal, 3-Pal, 4-Pal, Taz, 2-Thi, 3-Thi, or (X¹,X²,X³,X⁴,X⁵)Phe;

A⁵ is D-Phe, D-1-Nal, D-2-Nal, D-Trp, D-Bal, D-(X¹,X²,X³,X⁴,X⁵)Phe, L-Phe or D-(Et)Tyr;

A⁶ is Arg, hArg, Dab, Dap, Lys, Orn, or HN-CH((CH₂)_n-N(R⁴R⁵))-C(O);

A⁷ is Trp, 1-Nal, 2-Nal, Bal, Bip, D-Trp, D-1-Nal, D-2-Nal, D-Bal or D-Bip;

40 A⁸ is Gly, D-Ala, Acc, Ala, β-Ala, Gaba, Apn, Ahx, Aha, HN-(CH₂)_s-C(O), or deleted;

A⁹ is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Dab, Dap, Orn, or Lys;

A¹⁰ is Acc, HN-(CH₂)_t-C(O), L- or D-amino acid, or deleted;

R¹ is -OH, or -NH₂;

45 each of R² and R³ is independently for each occurrence selected from the group consisting of H, (C₁-C₃₀)alkyl, (C₁-C₃₀)heteroalkyl, (C₁-C₃₀)acyl, (C₂-C₃₀)alkenyl, (C₂-C₃₀)alkynyl, aryl(C₁-C₃₀)alkyl, aryl(C₁-C₃₀)acyl, substituted (C₁-C₃₀)alkyl, substituted (C₁-C₃₀)heteroalkyl, substituted (C₁-C₃₀)acyl, substituted (C₂-C₃₀)alkenyl, substituted (C₂-C₃₀)alkynyl, substituted aryl(C₁-C₃₀)alkyl, and substituted aryl(C₁-C₃₀)acyl;

50 R⁴ and R⁵ each is, independently for each occurrence, H, (C₁-C₄₀)alkyl, (C₁-C₄₀)heteroalkyl, (C₁-C₄₀)acyl, (C₂-C₄₀)alkenyl, (C₂-C₄₀)alkynyl, aryl(C₁-C₄₀)alkyl, aryl (C₁-C₄₀) acyl, substituted (C₁-C₄₀)alkyl, substituted (C₁-C₄₀)heteroalkyl, substituted (C₁-C₄₀)acyl, substituted (C₂-C₄₀)alkenyl, substituted (C₂-C₄₀)alkynyl, substituted aryl (C₁-C₄₀)alkyl, substituted aryl(C₁-C₄₀)acyl, (C₁-C₄₀)alkylsulfonyl, or -C(NH)-NH₂;

m is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or 7;

n is, independently for each occurrence, 1, 2, 3, 4 or 5;

55 s is, independently for each occurrence, 1, 2, 3, 4, 5, 6, or 7;

t is, independently for each occurrence, 1, 2, 3, 4, 5, 6, or 7;

X¹, X², X³, X⁴, and X⁵ each is, independently for each occurrence, H, F, Cl, Br, I, (C₁₋₁₀)alkyl, substituted (C₁₋₁₀)alkyl, (C₂₋₁₀)alkenyl, substituted (C₂₋₄₀)alkenyl, (C₂₋₁₀)alkynyl, substituted (C₂₋₁₀)alkynyl, aryl, substituted aryl, OH, NH₂,

NO₂, or CN;

provided that

- 5 (I). when R⁴ is (C₁-C₄₀)acyl, aryl(C₁-C₄₀)acyl, substituted (C₁-C₄₀)acyl, substituted aryl(C₁-C₄₀)acyl, (C₁-C₄₀)alkyl-sulfonyl, or -C(NH)-NH₂, then R⁵ is H or (C₁-C₄₀)alkyl, (C₁-C₄₀)heteroalkyl, (C₂-C₄₀)alkenyl, (C₂-C₄₀)alkynyl, aryl(C₁-C₄₀)alkyl, substituted (C₁-C₄₀)alkyl, substituted (C₁-C₄₀)heteroalkyl, substituted (C₂-C₄₀)alkenyl, substituted (C₂-C₄₀)alkynyl, or substituted aryl(C₁-C₄₀)alkyl;
- 10 (II). when R² is (C₁-C₃₀)acyl, aryl(C₁-C₃₀)acyl, substituted (C₁-C₃₀)acyl, or substituted aryl(C₁-C₃₀)acyl, then R³ is H, (C₁-C₃₀)alkyl, (C₁-C₃₀)heteroalkyl, (C₂-C₃₀)alkenyl, (C₂-C₃₀)alkynyl, aryl(C₁-C₃₀)alkyl, substituted (C₁-C₃₀)alkyl, substituted (C₁-C₃₀)heteroalkyl, substituted (C₂-C₃₀)alkenyl, substituted (C₂-C₃₀)alkynyl, or substituted aryl(C₁-C₃₀)alkyl;
- (III). either A³ or A⁸ or both must be present in said compound;
- (IV). when A² is Cys, D-Cys, hCys, D-hCys, Pen, or D-Pen, then A⁹ is Cys, D-Cys, hCys, D-hCys, Pen, or D-Pen;
- 15 (V). when A² is Asp or Glu, then A⁹ is Dab, Dap, Orn, or Lys;
- (VI). when A⁸ is Ala or Gly, then A¹ is not Nle; and
- (VII). when A¹ is deleted, then R² and R³ cannot both be H;

or a pharmaceutically acceptable salt thereof.

- 20 **[0016]** An example of a group of compounds of the immediate foregoing formula, is where A¹ is A6c, Gaba, Nle, Met, Phe, D-Phe, D-2-Nal, hPhe, Chg, D-Chg, Cha, hCha, hPro, hLeu, Nip, β-hMet, or Oic;
- A² is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp, or Glu;
- A³ is Gly, Ala, D-Ala, D-Glu, β-Ala, Gaba, Aib, or deleted;
- 25 A⁴ is His;
- A⁵ is D-Phe, D-1-Nal, D-2-Nal, D-Trp, D-Bal, or D-(Et)Tyr;
- A⁶ is Arg, or hArg;
- A⁷ is Trp, Bip, D-Trp, 1-Nal, or 2-Nal;
- A⁸ is A6c, Ala, β-Ala, Gaba, Apn, or Ahx;
- 30 A⁹ is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, or Lys;
- A¹⁰ is Thr, or deleted

or a pharmaceutically acceptable salt thereof.

[0017] An example of a group of compounds of the immediately foregoing group of compounds is where R² and R³ each is, independently, H, acyl, n-propanoyl, or n-butanoyl or a pharmaceutically acceptable salt thereof.

- 35 **[0018]** An example of a compound of formula (I) is where said compound is of the formula:

A¹ is Acc, Arg, D-Arg, Cha, D-Cha, hCha, Chg, D-Chg, Gaba, Ile, Leu, hLeu, β-hMet, 2-Nal, D-2-Nal, Nip, Nle, Oic, Phe, D-Phe, hPhe, hPro, Val or deleted;

A² is Cys, D-Cys, Pen or Asp;

40 A³ is Gly, Ala, β-Ala, Gaba, Aib, D-Ala, D-Abu, D-Cha, D-Ile, D-Leu, D-Tle, D-Val or deleted;

A⁴ is His or 3-Pal;

A⁵ is D-Phe, D-2-Nal or D-(Et)Tyr;

A⁶ is Arg or hArg;

A⁷ is Trp, 1-Nal, 2-Nal, Bal, Bip or D-Trp;

45 A⁸ is Gly, D-Ala, Acc, Ala, β-Ala, Gaba, Apn, Ahx, Aha or deleted;

A⁹ is Cys, D-Cys, Pen or Lys;

A¹⁰ is Thr or deleted;

wherein at least one of A³ or A⁸ is deleted, but not both,

- 50 or a pharmaceutically acceptable salt thereof.

[0019] Examples of compounds of the immediately foregoing group of compounds are those where said compound is of the formula:

- 55 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH₂;
- Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH₂;
- Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH₂;
- D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH₂;
- D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH₂;

D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH₂;
 Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 5 Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 10 Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 15 Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(D-Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 20 Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 25 Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 30 Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 35 Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 40 n-butanoyl-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-β-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH₂;
 45 Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH₂;
 Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH₂;
 Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH₂;
 Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-D-Ala-Lys)-NH₂;
 50 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-β-Ala-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH₂;
 55 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-NH₂;

Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH₂;
 n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH₂;
 5 n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-Nal-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Bal-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Glu-His-D-Phe-Arg-Trp-Cys)-NH₂;
 10 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-D-Ala-Lys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH₂;
 Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂;
 Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂;
 15 D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH₂;
 D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH₂;
 D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH₂;
 D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH₂;
 D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH₂;
 20 D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH₂;
 Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH₂;
 Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH₂;
 Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;
 25 Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH₂;
 30 Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂;
 Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂;
 Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 35 Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 40 Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;
 Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH₂;
 45 Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-p-Ala-Lys)-NH₂;
 Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH₂;
 Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH₂;
 50 Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-OH;
 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH;
 D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-OH;
 D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-OH;
 55 D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-OH;
 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH;
 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH;
 Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;

Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;
 Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
 Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
 5 Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
 Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
 Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH;
 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH;
 10 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp- β -Ala-Cys)-OH;
 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-OH;
 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-OH;
 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-OH;
 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-OH;
 15 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-OH;
 Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;
 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH; or
 Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH₂; or

or pharmaceutically acceptable salts thereof.

[0020] Examples of the immediately foregoing group of compounds are compounds of the formula:

Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 25 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH; or
 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH;

or pharmaceutically acceptable salts thereof.

[0021] An example of a compound of formula (I) is where said compound is of the formula:

A¹ is Arg, D-Arg, Cha, hCha, Chg, D-Chg, Ile, Leu, 2-Nal, Nle, Phe, D-Phe, hPhe, Val or deleted;
 35 A² is Cys, Pen or Asp;
 A³ is D-Ala, D-Abu, D-Cha, D-Ile, D-Leu, D-Tle, D-Val or deleted;
 A⁴ is His or 3-Pal;
 A⁵ is D-Phe, D-2-Nal or D-(Et)Tyr;
 A⁶ is Arg or hArg;
 40 A⁷ is Trp, 2-Nal, Bal, Bip or D-Trp;
 A⁸ is Gly, Ala, β -Ala, Gaba, Apn, Ahx, or deleted;
 A⁹ is Cys, D-Cys, Pen or Lys;
 A¹⁰ is Thr or deleted;
 each of R² and R³ is independently selected from the group consisting of H or acyl;

or a pharmaceutically acceptable salt thereof.

[0022] Examples of the immediately foregoing group of compounds are compounds of the formula:

Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 50 Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂;
 Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂;
 Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂;
 Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂;
 55 Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH₂;
 Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp- β -Ala-D-Cys)-Thr-NH₂;

Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂;
 Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH₂;
 5 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH₂;
 D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH₂;
 D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH₂;
 10 Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 15 Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-NH₂;
 Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂;
 D-Phe-c(Cys-His-D-Phe-hArg-Trp-P-Ala-D-Cys)-Thr-NH₂;
 20 D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH₂;
 D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH₂;
 D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH₂;
 D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH₂;
 Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH₂;
 25 Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;
 Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH₂;
 30 Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂;
 35 Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 40 Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-3Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;
 Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH₂;
 45 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH₂;
 Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH₂;
 50 Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH₂;
 Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH₂; or
 Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH₂;
 55

or a pharmaceutically acceptable salt thereof.

[0023] An example of a compound of formula (I) is where said compound is of the formula:

A¹ is Arg, D-Arg, hArg or D-hArg;

or a pharmaceutically acceptable salt thereof.

[0024] An example of a compound of the immediately foregoing group of compounds is where said compound is of the formula:

5 A² is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp, or Glu;
 A³ is Gly, Ala, D-Ala, D-Glu, β-Ala, Gaba, Aib, or deleted;
 A⁴ is His;
 A⁵ is D-Phe, D-1-Nal, D-2-Nal, D-Trp, D-Bal, or D-(Et)Tyr;
 A⁶ is Arg, or hArg;
 10 A⁷ is Trp, Bip, D-Trp, 1-Nal, or 2-Nal;
 A⁸ is A6c, Ala, β-Ala, Gaba, Apn, Ahx;
 A⁹ is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, or Lys;
 A¹⁰ is Thr, or deleted;

15 or a pharmaceutically acceptable salt thereof.

[0025] An example of a compound of the immediately foregoing group of compounds is where R² and R³ each is, independently, H, acyl, n-propanoyl, or n-butanoyl or a pharmaceutically acceptable salt thereof.

[0026] An example of a compound of the immediately foregoing group of compounds is where said compound is of the formula:

20 A² is Cys or Asp;
 A³ is D-Ala or deleted;
 A⁴ is His;
 A⁵ is D-Phe or D-2-Nal;
 25 A⁶ is Arg;
 A⁷ is Trp;
 A⁸ is Ala, Gaba or deleted;
 A⁹ is Cys, Pen or Lys;
 A¹⁰ is deleted;

30 or a pharmaceutically acceptable salt thereof.

[0027] An example of a compound of the immediately foregoing group of compounds is where R² and R³ each is, independently, H or acyl; or a pharmaceutically acceptable salt thereof.

[0028] Examples of the immediately foregoing group of compounds are compounds of the formula:

35 Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂;
 Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂;
 40 Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂;
 Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂;
 Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH₂;
 Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH₂; or
 Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH₂;
 45 or pharmaceutically acceptable salts thereof.

[0029] Examples of the immediately foregoing group of compounds are compounds of the formula:

50 Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂; or
 Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH₂;

or a pharmaceutically acceptable salt thereof.

[0030] An example of the immediately foregoing group of compounds is a compound of the formula:

55 Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 or a pharmaceutically acceptable salt thereof.

[0031] An example of the immediately foregoing group of compounds is a compound of the formula:

Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂;

or a pharmaceutically acceptable salt thereof.

[0032] An example of the immediately foregoing group of compounds is a compound of the formula:

Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH₂;

or a pharmaceutically acceptable salt thereof.

5 **[0033]** Also described herein is a compound according formula (II):

(R²R³)-A¹-c(A²-A³-A⁴-A⁵-A⁶-A⁷-A⁸-A⁹)-NH₂

wherein:

A¹ is Nle or deleted;

10 A² is Cys or Asp;

A³ is Glu or D-Ala;

A⁴ is His;

A⁵ is D-Phe;

A⁶ is Arg;

15 A⁷ is Trp, 2-Nal or Bal;

A⁸ is Gly, Ala, D-Ala, β-Ala, Gaba or Apn;

A⁹ is Cys or Lys;

each of R² and R³ is independently selected from the group consisting of H or (C₁-C₆)acyl;

provided that

20

(I). when R² is (C₁-C₆)acyl, then R³ is H; and

(II). when A² is Cys, then A⁹ is Cys,

or a pharmaceutically acceptable salt thereof.

25 **[0034]** Examples of the immediately foregoing group of compounds are compounds of the formula:

Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH₂;

Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH₂;

Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-p-Ala-Cys)-NH₂;

30 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;

Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH₂;

Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH₂;

Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH₂;

Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH₂;

35 Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH₂;

Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH₂;

Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH₂;

Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂; or

Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH₂;

40

or a pharmaceutically acceptable salt thereof.

[0035] Another example of a compound of formula (I) or formula (II) is each of the compounds that are specifically enumerated herein below in the Examples section of the present disclosure, or a pharmaceutically acceptable salt thereof.

45 **[0036]** Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

[0037] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, wherein said compound is a selective melanocortin-4 receptor agonist.

50 **[0038]** Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, wherein said compound is a selective melanocortin 4 receptor agonist with a functional activity characterized by an EC₅₀ at least 15- fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.

55 **[0039]** Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, wherein said compound is a selective melanocortin 4 receptor agonist with a functional activity characterized by an EC₅₀ at least 17-fold more selective for the human melanocortin 4 receptor than

for the human melanocortin 3 receptor, an EC₅₀ at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an EC₅₀ at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor, or an EC₅₀ at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.

[0040] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating an acute or chronic inflammatory disease or medical condition such as general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock.

[0041] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a disease or medical condition with an autoimmune component such as rheumatoid arthritis, gouty arthritis and multiple sclerosis.

[0042] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a metabolic disease or medical condition accompanied by weight gain such as obesity, feeding disorders and Prader-Willi Syndrome. The disease or condition treated may be obesity. The disease or condition treated may be a feeding disorder.

[0043] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for decreasing food intake, for decreasing body weight or a combination thereof. Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, which is useful for diminishing food intake, decreasing body weight, or a combination thereof, wherein the active ingredient is one or more of the following compounds: Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂, Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂, D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH₂, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂ or Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH₂. Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, which is useful for diminishing food intake, decreasing body weight, or a combination thereof, wherein the active ingredient is Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂. Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, which is useful for diminishing food intake, decreasing body weight, or a combination thereof, wherein the active ingredient is Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂. Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, which is useful for diminishing food intake, decreasing body weight, or a combination thereof, wherein the active ingredient is Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH₂.

[0044] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, which is useful for decreasing appetite without compromising body weight. Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for decreasing food consumption while increasing body weight.

[0045] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a metabolic disease or medical condition accompanied by weight loss such as anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly. The disease or condition treated may be anorexia. The disease or condition treated may be bulimia. The disease or condition treated may be AIDS wasting or wasting in frail elderly. The disease or condition treated may be cachexia or cancer cachexia.

[0046] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a neoplastic disease or medical condition such as skin cancer and cancer cachexia.

[0047] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a reproductive or sexual medical condition such as en-

dometriosis, uterine bleeding, sexual dysfunction, erectile dysfunction and decreased sexual response in females.

[0048] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a disease or medical condition resulting from treatment or insult to an organism such as organ transplant rejection, ischemia and reperfusion injury, wounding and spinal cord injury, and weight loss due to a medical procedure selected from the group consisting of chemotherapy, radiation therapy, temporary or permanent immobilization and dialysis.

[0049] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a cardiovascular disease or medical condition such as hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders and cardiac cachexia.

[0050] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a pulmonary disease or medical condition such as acute respiratory distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease and asthma.

[0051] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for enhancing immune tolerance and treating allergies.

[0052] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a dermatological disease or medical condition such as psoriasis, skin pigmentation depletion, acne and keloid formation.

[0053] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for treating a behavioral or central nervous system or neuronal disease or medical condition such as anxiety, depression, memory dysfunction and neuropathic pain.

[0054] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for treating a renal disease or medical condition such as renal cachexia and natriuresis.

[0055] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for modulating ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection and nerve growth.

[0056] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for modulating bone metabolism, bone formation and bone development.

[0057] Also described herein is a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for inhibiting alcohol consumption, for reducing alcohol consumption, for treating alcoholism, or for treating alcohol abuse. The compound of the composition useful for inhibiting alcohol consumption, for reducing alcohol consumption, for treating alcoholism, or for treating alcohol abuse may be a selective melanocortin 4 receptor agonist. The compound of the composition useful for inhibiting alcohol consumption may be a selective melanocortin 4 receptor agonist, or a pharmaceutically acceptable salt thereof, with a functional activity characterized by an EC₅₀ at least 15-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor. The compound of the composition useful for inhibiting alcohol consumption may be a selective melanocortin 4 receptor agonist, or a pharmaceutically acceptable salt thereof, with a functional activity characterized by an EC₅₀ at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an EC₅₀ at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an EC₅₀ at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor, or an EC₅₀ at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.

[0058] Also described herein is the use of a therapeutically effective amount of a melanocortin 4 receptor agonist compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful for inhibiting alcohol consumption, for reducing alcohol consumption, for treating

alcoholism, or for treating alcohol abuse in a subject in need of such treatment.

[0059] Also described herein is a method of eliciting an agonist or an antagonist effect from a melanocortin receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

[0060] Also described herein is a method of eliciting an agonist or an antagonist effect from a melanocortin receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, wherein said compound is a selective melanocortin 4 receptor agonist.

[0061] Also described herein is a method of eliciting an agonist or an antagonist effect from a melanocortin receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, wherein said compound is a selective melanocortin 4 receptor agonist with a functional activity characterized by an EC₅₀ at least 15-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.

[0062] Also described herein is a method of eliciting an agonist or an antagonist effect from a melanocortin receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, wherein said compound is a selective melanocortin 4 receptor agonist with a functional activity characterized by an EC₅₀ at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an EC₅₀ at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an EC₅₀ at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor, or an EC₅₀ at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.

[0063] Also described herein is a method of treating an acute or chronic inflammatory disease or medical condition such as general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

[0064] Also described herein is a method of treating a disease or medical condition with an autoimmune component such as rheumatoid arthritis, gouty arthritis and multiple sclerosis by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

[0065] Also described herein is a method of treating a metabolic disease or medical condition accompanied by weight gain such as obesity, feeding disorders and Prader-Willi Syndrome by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof. The disease or condition treated may be obesity. The disease or condition treated may be a feeding disorder.

[0066] Also described herein is a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof. Also described herein is a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said compound is Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂, Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂, D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH₂, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂, or Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH₂. Also described herein is a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂. Also described herein is a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said compound is Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂. Also described herein is a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH₂.

[0067] Also described herein is a method of decreasing appetite without compromising body weight by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof. Also described herein is a method of decreasing food consumption while increasing body weight by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically

acceptable salt thereof.

[0068] Also described herein is a method of treating a metabolic disease or medical condition accompanied by weight loss such as anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof. The foregoing method may be used to treat anorexia. The foregoing method may be used to treat bulimia. The foregoing method may be used to treat AIDS wasting or wasting in frail elderly. The foregoing method may be used to treat cachexia or cancer cachexia.

[0069] Also described herein is a method of treating a neoplastic disease or medical condition such as skin cancer and cancer cachexia by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

[0070] Also described herein is a method of treating a reproductive or sexual medical condition such as endometriosis, uterine bleeding, sexual dysfunction, erectile dysfunction and decreased sexual response in females by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

[0071] Also described herein is a method of treating a disease or medical condition resulting from treatment or insult to an organism such as organ transplant rejection, ischemia and reperfusion injury, wounding and spinal cord injury, and weight loss due to a medical procedure selected from the group consisting of chemotherapy, radiation therapy, temporary or permanent immobilization and dialysis by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

[0072] Also described herein is a method of treating a cardiovascular disease or medical condition such as hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders and cardiac cachexia by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

[0073] Also described herein is a method of treating a pulmonary disease or medical condition such as acute respiratory distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease and asthma by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

[0074] Also described herein is a method of enhancing immune tolerance or treating allergies by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

[0075] Also described herein is a method of treating dermatological disease or medical condition such as psoriasis, skin pigmentation depletion, acne and keloid formation by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

[0076] Also described herein is a method of treating a behavioral or central nervous system or neuronal disease or medical condition such as anxiety, depression, memory dysfunction and neuropathic pain by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

[0077] Also described herein is a method of treating a renal disease or medical condition such as renal cachexia and natriuresis by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

[0078] Also described herein is a method of modulating a normalizing or homeostatic activity such as ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxine release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection and nerve growth by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

[0079] Also described herein is a method of modulating a normalizing or homeostatic activity such as bone metabolism, bone formation and bone development by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

[0080] Also described herein is a method of inhibiting alcohol consumption, for reducing alcohol consumption, for treating alcoholism, or for treating alcohol abuse by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof. The compound may be a selective melanocortin 4 receptor agonist. The compound of the composition useful for inhibiting alcohol consumption may be a selective melanocortin 4 receptor agonist, or a

pharmaceutically acceptable salt thereof, with a functional activity characterized by an EC₅₀ at least 15- fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor. The compound of the composition useful for inhibiting alcohol consumption may be a selective melanocortin 4 receptor agonist, or a pharmaceutically acceptable salt thereof, with a functional activity characterized by an EC₅₀ at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an EC₅₀ at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an EC₅₀ at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor, or an EC₅₀ at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.

[0081] Also described herein is the use of a therapeutically effective amount of a melanocortin 4 receptor agonist or antagonist compound according formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to treat a disease and/or medical condition selected from the group consisting of acute and chronic inflammatory diseases such as general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock; diseases with an autoimmune component such as rheumatoid arthritis, gouty arthritis and multiple sclerosis; metabolic diseases and medical disorders accompanied by weight gain such as obesity, feeding disorders and Prader-Willi Syndrome; metabolic diseases and medical disorders accompanied by weight loss such as anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly; diabetes, diabetological related conditions and complications of diabetes such as retinopathy; neoplastic proliferation such as skin cancer and prostate cancer; reproductive or sexual medical conditions such as endometriosis and uterine bleeding in women, sexual dysfunction, erectile dysfunction and decreased sexual response in females; diseases or conditions resulting from treatment or insult to the organism such as organ transplant rejection, ischemia and reperfusion injury, spinal cord injury and wounding, as well as weight loss caused chemotherapy, radiation therapy, temporary or permanent immobilization or dialysis; cardiovascular diseases or conditions such as hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders and cardiac cachexia; pulmonary diseases or conditions such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma and pulmonary fibrosis; to enhance immune tolerance and to combat assaults to the immune system such as those associated with certain allergies or organ transplant rejection; treatment of dermatological diseases and conditions such as psoriasis, skin pigmentation depletion, acne, keloid formation and skin cancer; behavioral, central nervous system and neuronal disorders such as anxiety, depression, memory dysfunction, and neuropathic pain; and renal conditions or diseases such as the treatment of renal cachexia and natriuresis.

[0082] Also described herein is the use of a therapeutically effective amount of a melanocortin 4 receptor agonist or antagonist compound according formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to modulate normalizing or homeostatic activities such as ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection, nerve growth, bone metabolism, bone formation and bone development.

[0083] It will be appreciated that therapeutic interventions addressing both normal physiological and pathophysiological processes which utilize the melanocortin receptors are also contemplated.

[0084] Additional objects, advantages, and features of the present invention will become apparent from the following description and appended claims, taken in conjunction with the accompanying drawings.

[0085] The compounds of formulae (I) or (II) are ligands for at least one of the melanocortin receptors (MC1-R, MC2-R, MC3-R, MC4-R and MC5-R) and a selection thereof were tested for their ability to act as a ligand in the *in vitro* assay described below.

BRIEF DESCRIPTION OF THE DRAWINGS:

[0086]

Figure 1A: Mean difference in food consumed from vehicle in fasted rats 6 hours after administration of 100 nmole/Kg of selected compounds.

Figure 1B. Mean difference in food consumed from vehicle in fasted rats 6 hours after administration of 500 nmole/Kg of selected compounds.

Figure 2A. Cumulative difference in mean food intake from vehicle in rats after administration of various concentrations of Compound A.

Figure 2B. Cumulative mean body weight difference from vehicle in rats after administration of various concentrations of Compound A.

Figure 3A. Cumulative difference in mean food intake from vehicle in rats after administration of selected compounds.


Figure 3B. Cumulative mean body weight difference from vehicle in rats after administration of selected compounds.
Figure 4A. Cumulative difference in mean food intake from vehicle in rats after administration of selected compounds.
Figure 4B. Cumulative mean body weight difference from vehicle in rats after administration of selected compounds.

DETAILED DESCRIPTION OF THE INVENTION

[0087] The nomenclature used to define the peptides is that typically used in the art wherein the amino group at the N-terminus appears to the left and the carboxyl group at the C-terminus appears to the right. Where the amino acid has isomeric forms, it is the L form of the amino acid that is represented unless otherwise explicitly indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.



Nomenclature and Abbreviations

Symbol	Meaning
Abu	α -aminobutyric acid
Ac	acyl group
Acc	1-amino-1-cyclo(C ₃ -C ₉)alkyl carboxylic acid
A3c	1-amino-1-cyclopropanecarboxylic acid
A4c	1-amino-1-cyclobutanecarboxylic acid
A5c	1-amino-1-cyclopentanecarboxylic acid
A6c	1-amino-1-cyclohexanecarboxylic acid
Aha	7-aminoheptanoic acid
Ahx	6-aminohexanoic acid
Aib	α -aminoisobutyric acid
Ala or A	alanine
β -Ala	β -alanine
Apn	5-aminopentanoic acid (HN-(CH ₂) ₄ -C(O))
Arg or R	arginine
hArg	homoarginine
Asn or N	asparagine
Asp or	D aspartic acid
Bal	3-benzothienylalanine
Bip	4,4'-biphenylalanine, represented by the structure



Bpa	4-benzoylphenylalanine
4-Br-Phe	4-bromo-phenylalanine
Cha	β -cyclohexylalanine
hCha	homo-cyclohexylalanine
Chg	cyclohexylglycine
Cys or C	cysteine
hCys	homocysteine
Dab	2,4-diaminobutyric acid
Dap	2,3-diaminopropionic acid

(continued)

	Symbol	Meaning
	Dip	β,β -diphenylalanine
5	Doc	8-amino-3,6-dioxaoctanoic acid with the structure of:
		
	2-Fua	β -(2-furyl)-alanine
10	Gaba	4-aminobutyric acid
	Gln or Q	glutamine
	Glu or E	glutamic acid
	Gly or G	glycine
	His or H	histidine
15	3-Hyp	trans-3-hydroxy-L-proline, i.e., (2S, 3S)-3-hydroxypyrrolidine-2-carboxylic acid
	4-Hyp	4-hydroxyproline, i.e., (2S, 4R)-4-hydroxypyrrolidine-2-carboxylic acid
	Ile or I	isoleucine
	Leu or L	leucine
	hLeu	homoleucine
20	Lys or K	lysine
	Met or M	methionine
	β -hMet	β -homomethionine
	1-Nal	β -(1-naphthyl)alanine:
	2-Nal	β -(2-naphthyl)alanine
25	Nip	nipecotic acid
	Nle	norleucine
	Oic	octahydroindole-2-carboxylic acid
	Orn	ornithine
30	2-Pal	β -(2-pyridyl)alanine
	3-Pal	β -(3-pyridyl)alanine
	4-Pal	β -(4-pyridyl)alanine
	Pen	penicillamine
	Phe or F	phenylalanine
35	hPhe	homophenylalanine
	Pro or P	proline
	hPro	homoproline
	Ser or S	serine
40	Tie	tert-Leucine
	Taz	β -(4-thiazolyl)alanine
	2-Thi	β -(2-thienyl)alanine
	3-Thi	β -(3-thienyl)alanine
	Thr or T	threonine
45	Trp or W	tryptophan
	Tyr or Y	tyrosine
	D-(Et)Tyr	has a structure of
50		
55	Val or V	valine

[0088] Certain other abbreviations used herein are defined as follows:

	Boc:	<i>tert</i> -butoxycarbonyl
	Bzl:	benzyl
5	DCM:	dichloromethane
	DIC:	N, N-diisopropylcarbodiimide
	DIEA:	diisopropylethyl amine
	Dmab:	4-{N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl)-amino} benzyl
	DMAP:	4-(dimethylamino)pyridine
10	DMF:	dimethylformamide
	DNP:	2,4-dinitrophenyl
	Fm:	fluorenylmethyl
	Fmoc:	fluorenylmethyloxycarbonyl
	For:	formyl
15	HBTU:	2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
	cHex:	cyclohexyl
	HOAT:	O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
	HOBt:	1-hydroxy-benzotriazole
	MBHA:	4-methylbenzhydrylamine
20	Mmt:	4-methoxytrityl
	NMP:	N-methylpyrrolidone
	O-tBu:	oxy- <i>tert</i> -butyl
	Pbf:	2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl
	PyBroP:	bromo-tris-pyrrolidino-phosphonium hexafluorophosphate
25	tBu:	<i>tert</i> -butyl
	TIS:	triisopropylsilane
	TOS:	tosyl
	Trt:	trityl
	TFA:	trifluoro acetic acid
30	TFFH:	tetramethylfluoroformidinium hexafluorophosphate
	Z:	benzyloxycarbonyl


[0089] Unless otherwise indicated, with the exception of the N-terminal amino acid, all abbreviations (e.g. Ala) of amino acids in this disclosure stand for the structure of -NH-C(R)(R')-CO-, wherein R and R' each is, independently, hydrogen or the side chain of an amino acid (e.g., R = CH₃ and R' = H for Ala), or R and R' may be joined to form a ring system.

[0090] For the N-terminal amino acid, the abbreviation stands for the structure of:




[0091] The designation "NH₂" in e.g., Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂, indicates that the C-terminus of the peptide is amidated. Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys), or alternatively Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH, indicates that the C-terminus is the free acid.


[0092] "-c(Cys-Cys)-" or "-cyclo(Cys-Cys)-" denotes the structure:



55
"-c(Cys-Pen)-" or "-cyclo(Cys-Pen)-" denotes the structure:



"-c(Asp-Lys)-" or "-cyclo(Asp-Lys)-" denotes the structure:



[0093] "Acy" refers to $R-C(O)-$, where R is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, aryl, alkylaryl, or substituted alkylaryl, and is indicated in the general formula of a particular embodiment as "Ac".

[0094] "Alkyl" refers to a hydrocarbon group containing one or more carbon atoms, where multiple carbon atoms if present are joined by single bonds. The alkyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups.

[0095] "Hydroxyalkyl" refers to an alkyl group wherein one or more hydrogen atoms of the hydrocarbon group are substituted with one or more hydroxy radicals, such as hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl and the like.

[0096] "Substituted alkyl" refers to an alkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH₂, -NHCH₃, -NO₂, and -C₁₋₂₀ alkyl, wherein said -C₁₋₂₀ alkyl optionally may be substituted with one or more substituents selected, independently for each occurrence, from the group consisting of halogens, -CF₃, -OCH₃, -OCF₃, and -(CH₂)₀₋₂₀-COOH. In different embodiments 1, 2, 3 or 4 substituents are present. The presence of -(CH₂)₀₋₂₀-COOH results in the production of an alkyl acid. Non-limiting examples of alkyl acids containing, or consisting of, -(CH₂)₀₋₂₀-COOH include 2-norbornane acetic acid, tert-butyric acid, 3-cyclopentyl propionic acid, and the like.

[0097] The term "halo" encompasses fluoro, chloro, bromo and iodo.

[0098] "Heteroalkyl" refers to an alkyl wherein one or more of the carbon atoms in the hydrocarbon group is replaced with one or more of the following groups: amino, amido, -O-, -S- or carbonyl. In different embodiments 1 or 2 heteroatoms are present.

[0099] "Substituted heteroalkyl" refers to a heteroalkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH₂, -NHCH₃, -NO₂, and -C₁₋₂₀ alkyl, wherein said -C₁₋₂₀ alkyl optionally may be substituted with one or more substituents selected, independently for each occurrence, from the group consisting of halogens, -CF₃, -OCH₃, -OCF₃, and -(CH₂)₀₋₂₀-COOH. In different embodiments 1, 2, 3 or 4 substituents are present.

[0100] "Alkenyl" refers to a hydrocarbon group made up of two or more carbons where one or more carbon-carbon double bonds are present. The alkenyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups.

[0101] "Substituted alkenyl" refers to an alkenyl wherein one or more hydrogens are replaced with one or more substituents selected from the group consisting of halogen (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH₂, -NHCH₃, -NO₂, and -C₁₋₂₀ alkyl, wherein said -C₁₋₂₀ alkyl optionally may be substituted with one or more substituents selected, independently for each occurrence, from the group consisting of halogens, -CF₃, -OCH₃, -OCF₃, and -(CH₂)₀₋₂₀-COOH. In different embodiments 1, 2, 3 or 4 substituents are present.

[0102] "Aryl" refers to an optionally substituted aromatic group with at least one ring having a conjugated pi-electron system, containing up to three conjugated or fused ring systems. Aryl includes carbocyclic aryl, heterocyclic aryl and biaryl groups. Preferably, the aryl is a 5- or 6-membered ring. Preferred atoms for a heterocyclic aryl are one or more sulfur, oxygen, and/or nitrogen. Non-limiting examples of aryl include phenyl, 1-naphthyl, 2-naphthyl, indole, quinoline, 2-imidazole, 9-anthracene, and the like. Aryl substituents are selected from the group consisting of -C₁₋₂₀ alkyl, -C₁₋₂₀ alkoxy, halogen (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH₂, -NO₂, -C₁₋₂₀ alkyl substituted with halogens, -CF₃, -OCF₃, and -(CH₂)₀₋₂₀-COOH. In different embodiments the aryl contains 0, 1, 2, 3, or 4 substituents.

[0103] "Alkylaryl" refers to an "alkyl" joined to an "aryl".

[0104] The term "(C₁-C₁₂)hydrocarbon moiety" encompasses alkyl, alkenyl and alkynyl and in the case of alkenyl and alkynyl there is C₂-C₁₂.

[0105] As used herein, the term "normalizing" functions or activities refers to those types of functions which may be considered to be involved in normal body function or homeostasis of an organism. Such functions include but are not limited to activities and functions affecting body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels and the like.

[0106] As used herein, compounds which are considered to be "selective" for a particular melanocortin receptor are those compounds with a functional activity characterized by an EC₅₀ at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 15-fold, at least about 17-fold, at least about 90-fold, at least about 200-fold, at least about 3000-fold or at least about 10,000-fold, or even greater, selectivity for any melanocortin receptor as compared to any other melanocortin receptor. For example, a selective melanocortin 4 receptor agonist of the invention exhibits a functional activity characterized by an EC₅₀ at least about 15-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor. Also for example, a selective melanocortin 4 receptor agonist of the invention exhibits a functional activity characterized by an EC₅₀ at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.

Synthesis

[0107] The peptides herein can be prepared by standard solid phase peptide synthesis. See, e.g., Stewart, J.M., et al., Solid Phase Synthesis (Pierce Chemical Co., 2d ed. 1984). The substituents R² and R³ of the above generic formula may be attached to the free amine of the N-terminal amino acid by standard methods known in the art. For example, alkyl groups, e.g., (C₁-C₃₀)alkyl, may be attached using reductive alkylation. Hydroxyalkyl groups, e.g., (C₁-C₃₀)hydroxyalkyl, may also be attached using reductive alkylation wherein the free hydroxyl group is protected with a t-butyl ester. Acyl groups, e.g., COE¹, may be attached by coupling the free acid, e.g., E¹COOH, to the free amine of the N-terminal amino acid by mixing the completed resin with 3 molar equivalents of both the free acid and diisopropylcarbodiimide in methylene chloride for one hour. If the free acid contains a free hydroxyl group, e.g., p-hydroxyphenylpropionic acid, then the coupling should be performed with an additional 3 molar equivalents of HOBt.

[0108] When R¹ is -NH₂, the synthesis of the peptide starts with an Fmoc-amino acid which is coupled to the Rink Amide MBHA resin. If R¹ is -OH, the synthesis of the peptide starts with a Fmoc-amino acid which is coupled to Wang resin.

[0109] In the synthesis of a peptide herein containing A6c and/or Aib, the coupling time is 2 hours for these residues and the residue immediately following them.

[0110] The following examples describe synthetic methods for making a peptide herein, which methods are well-known to those skilled in the art. Other methods are also known to those skilled in the art.

EXAMPLES

Reference Example 1: Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂

[0111] The title peptide was synthesized on an Advanced ChemTech model 396® multiple peptide synthesizer (Louisville, KY 40228) using Fluorenylmethyloxycarbonyl (Fmoc) chemistry. A Rink Amide 4-methylbenzylhydramine (MBHA) resin (Novabiochem®, San Diego, CA) with substitution of 0.58 mmol/g was used. The Fmoc amino acids (Novabiochem®, CA and Chem-Impex®, IL) used were Fmoc-Nle-OH, Fmoc-Cys(Trt)-OH, Fmoc-D-Ala-OH, Fmoc-His(Trt)-OH, Fmoc-D-Phe-OH, Fmoc-Arg(Pbf)-OH, and Fmoc-Trp(Boc)-OH. The synthesis was carried out on a 0.035 mmol scale. The Fmoc groups were removed by treatment with 25% piperidine in N,N-dimethylformamide (DMF) for 30 minutes. In each coupling step, the Fmoc amino acid (10 eq, 0.35 mmol), N, N-diisopropylcarbodiimide (DIC) (10 eq, 0.35 mmol), and 1-hydroxy-benzotriazole (HOBt) (10 eq, 0.35 mmol) were used in DMF (1.4 mL). After washing with DMF, double-coupling was performed with the Fmoc-amino acid (10 eq, 0.35 mmol), 2-(1-H-benzotriazole-1-yl)-1,1,2,3-tetramethyluronium hexafluorophosphate (HBTU) (8 eq, 0.28 mmol), HOBt (10 eq, 0.35 mmol), and diisopropylethylamine (DIEA) (20 eq, 0.7 mmol) in DMF (1.26 mL). The ACT 396® multiple peptide synthesizer was programmed to perform the following reaction cycle: (1) washing with DMF, (2) removing Fmoc protecting group with 25% piperidine in DMF for 30 minutes, (3) washing with DMF, (4) coupling with Fmoc amino acid in the presence of DIC and HOBt for 1 hour, (5) washing with DMF, (6) double-coupling with the same Fmoc amino acid in step 4 in the presence of HBTU, HOBt, and DIEA for 1 hour. The resin was coupled successively according to the sequence of the title peptide. After the peptide chain was assembled and the last Fmoc- protecting group was removed, the resin was washed completely by using DMF and dichloromethane (DCM).

[0112] To cleave the title peptide, the resin was treated with a solution (1.5 mL) of TFA, H₂O and triisopropylsilane (TIS) (v/v/v: 90/6.2/3.8) for 2 hours at room temperature. The resin was filtered off and the filtrate was poured into 30 mL of ether. The precipitate was collected by centrifugation. This crude product was dissolved in water (~7 mL) and the

pH of the aqueous solution was adjusted to ~7.5 by adding 2N NH_4HCO_3 . The solution was opened to the air for 72 hours at room temperature. The resulting crude product was purified on a reverse-phase preparative HPLC system with a column (4 x 43 cm) of C_{18} DYNAMAX-100 A^0 (Varian®, Walnut Creek, CA). The column was eluted over approximately 1 hour using a linear gradient of 85% A:15% B to 30% A:70% B, where A was 0.1% TFA in water and B was 0.1% TFA in acetonitrile. The fractions were checked by analytical HPLC and those containing pure product were pooled and lyophilized to dryness to give 10.3 mg (27% yield) of a white solid. Purity was assayed using HPLC and found to be approximately 88%. Electro-spray ionization mass spectrometry (ESI-MS) analysis gave the molecular weight at 1073.6 (in agreement with the calculated molecular weight of 1074.3).

Reference Example 2: Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)- NH_2

[0113] The title peptide was synthesized on an Applied Biosystems® (Foster City, CA) model 430A peptide synthesizer which was modified to do accelerated Boc-chemistry solid phase peptide synthesis. See Schnolzer, et al., Int. J. Peptide Protein Res., 40:180 (1992). 4-methylbenzhydrylamine (MBHA) resin (Peninsula®, Belmont, CA) with the substitution of 0.91 mmol/g was used. The Boc amino acids (Novabiochem®, San Diego, CA and Chem-Impex®, Wood Dale, IL) used were: Boc-Cha-OH, Boc-Asp(OFm)-OH, Boc-His(DNP)-OH, Boc-D-Phe-OH, Boc-Arg(Tos)-OH, Boc-Trp(For)-OH, Boc-Gaba-OH, and Boc-Lys(Fmoc)-OH. The synthesis was carried out on a 0.20 mmol scale. The Boc groups were removed by treatment with 100% TFA for 2 x 1 minute. Boc amino acids (2.5 mmol) were pre-activated with HBTU (2.0 mmol) and DIEA (1.0 mL) in 4 mL of DMF and were coupled without prior neutralization of the peptide-resin TFA salt. Coupling times were 5 minutes.

[0114] At the end of the assembly of Boc-Asp(OFm)-His(DNP)-D-Phe-Arg(Tos)-Trp(For)-Gaba-Lys(Fmoc)-MBHA, the peptide-resin was transferred into a reaction vessel on a shaker. The resin was treated twice with 25% piperidine in DMF for 15 minutes per session, washed with DMF, and shaken with bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBrOP) (6 eq, 0.3 mmol), DIEA (1 mL), and 4-(dimethylamino)pyridine (DMAP) (24 mg) in DMF (2 mL) for 12 hours. After washing with DMF, the resin was treated twice with 100% TFA for 2 minutes per treatment, washed with DMF and DCM, and then dried under reduced pressure. One fourth of the peptide-resin (0.05 mmol) was used for the next coupling with Boc-Cha-OH (10 eq, 0.5 mmol) in the presence of HBTU (9 eq, 0.45 mmol) and DIEA (0.25 mL) in DMF for 10 minutes. After the deprotection with 100% TFA in two sessions lasting approximately 2 minutes each, the peptide-resin was then washed with DMF. The final capping step was done by shaking the resin with acetic anhydride (40 eq, 2.0 mmol) and DIEA (20 eq, 1.0 mmol) in DMF for 1 hour. After washing with DMF, the resin was treated twice with a solution of 20% mercaptoethanol/10% DIEA in DMF, each treatment lasting approximately 30 minutes, to remove the DNP group on the Histidine side chain. The formyl group on the side chain of Tryptophan was removed by shaking with a solution of 15% ethanolamine/ 15% water/ 70% DMF twice for 30 minutes per shaking. The peptide-resin was washed with DMF and DCM and dried under reduced pressure. The final cleavage was done by stirring the peptide-resin in 10 mL of HF containing 1 mL of anisole and dithiothreitol (30 mg) at 0°C for 75 minutes. HF was removed by a flow of nitrogen. The residue was washed with ether (6 x 10 mL) and extracted with 4N HOAc (6 x 10 mL).

[0115] The peptide mixture in the aqueous extract was purified on reverse-phase preparative high pressure liquid chromatography (HPLC) using a reverse phase VYDAC® C_{18} column (Nest Group®, Southborough, MA). The column was eluted with a linear gradient (10% to 50% of solution B over 40 minutes) at a flow rate of 10 mL/minute (Solution A = water containing 0.1% TFA; Solution B = acetonitrile containing 0.1% of TFA). Fractions were collected and checked on analytical HPLC. Those containing pure product were combined and lyophilized to dryness. 5.1 mg of a white solid was obtained. Yield was 8.9%. Purity was 94.5% based on analytical HPLC analysis. Electro-spray mass spectrometer (MS(ES))S analysis gave the molecular weight at 1148.5 (in agreement with the calculated molecular weight of 1148.3).

[0116] Other peptides herein can be prepared by a person of ordinary skill in the art using synthetic procedures analogous to those disclosed generally hereinabove and/or to those disclosed specifically in the foregoing examples, as were the compounds depicted in Tables 1A and 1B.

[0117] The following peptides can be made according to the appropriate procedures described above:

Ac-Nle-c(Asp-His-D-Phe-Arg-Trp- β -Ala-Lys)- NH_2 ;
 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)- NH_2 ;
 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)- NH_2 ;
 D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr- NH_2 ;
 D-Phe-c(Cys-His-D-Phe-Arg-Trp- β -Ala-D-Cys)-Thr- NH_2 ;
 D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr- NH_2 ;
 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)- NH_2 ;
 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)- NH_2 ;
 Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)- NH_2 ;
 Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)- NH_2 ;

Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH₂;
 5 Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH₂;
 10 Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(D-Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 15 Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 20 Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH₂;
 Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 25 Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 30 Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 n-butanoyl-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 35 Ac-β-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH₂;
 Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH₂;
 Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH₂;
 40 Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH₂;
 Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-D-Ala-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-β-Ala-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH₂;
 45 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH₂;
 50 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH₂;
 55 n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH₂;
 n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-Nal-Cys)-NH₂;

Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Bal-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Glu-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-D-Ala-Lys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH₂;
 5 Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂;
 Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂;
 D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH₂;
 D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH₂;
 10 D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH₂;
 D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH₂;
 D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH₂;
 D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH₂;
 15 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH₂;
 Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH₂;
 20 Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH₂;
 Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH₂;
 Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH₂;
 Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH₂;
 Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH₂;
 25 Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-p-Ala-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;
 30 Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH₂;
 35 Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH₂;
 Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂;
 Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂;
 Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 40 Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 45 Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;
 Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH₂;
 50 Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH₂;
 Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH₂;
 Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH₂;
 55 Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH₂;
 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-OH;
 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH;

D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-OH;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-OH;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH;
5 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH;
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
10 Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH;
15 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-OH;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-OH;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-OH;
20 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-OH;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-OH;
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
25 Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂;
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂;
Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂;
Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH₂;
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH₂;
30 Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH₂;
Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH₂;
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH₂; and
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH.

35 **[0118]** Other peptides herein can be prepared by a person of ordinary skill in the art using synthetic procedures analogous to those disclosed generally hereinabove and/or to those disclosed specifically in the foregoing examples, as were the compounds depicted in Tables 1A and 1B.

40 TABLES 1A and 1B - Molecular Weight and Purity for Selected Compounds

[0119]

Table 1A

Compound	Calculated Molecular Weight	Experimental Molecular Weight	Purity
45 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH ₂	1095.27	1095.2	96.4
50 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH ₂	1149.36	1149.05	96
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH ₂	1116.38	1115.8	98
55 D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH ₂	1167.38	1167.3	99

(continued)

	Compound	Calculated Molecular Weight	Experimental Molecular Weight	Purity
5	D-Phe-c(Cys-His-D-Phe-Arg-Trp- β -Ala-D-Cys)-Thr-NH ₂	1167.38	1167.5	93
	D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH ₂	1181.41	1181.9	99
10	Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH ₂	1102.35	1103	99
15	Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH ₂	1123.32	1123.9	99
	Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1121.31	1121.2	93
20	Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1193.37	1193.2	92.6
	Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂ ;	1149.36	1149.4	94.5
25	Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1109.3	1109.2	91.5
30	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	1074.3	1074.6	98.3
	Ac-Nle-c(Cys- β -Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	1074.3	1074.4	91
35	Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH ₂	1088.32	1088.4	93
	Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH ₂	1088.32	1088.4	80
40	Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH ₂	1060.27	1060.4	90
45	Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	1074.3	1074.4	93
	Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	1074.3	1074.4	81
50	Ac-Nle-c(D-Cys- β -Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	1074.3	1074.4	92
55	Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH ₂	1088.32	1088.4	94

(continued)

	Compound	Calculated Molecular Weight	Experimental Molecular Weight	Purity
5	Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH ₂	1088.32	1088.4	91
10	Ac-Nle-c(D-Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH ₂	1060.27	1060.4	96
	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH ₂	1074.3	1074.4	66
15	Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH ₂	1074.3	1074.2	94
	Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH ₂	1088.32	1088.2	93
20	Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH ₂	1088.32	1088.4	90
25	Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-D-Cys)-NH ₂	1060.27	1060.4	91
	Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH ₂	1074.3	1074.4	65
30	Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH ₂	1074.3	1074.2	93
35	Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH ₂	1074.3	1074.4	92
	Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH ₂	1088.32	1088.4	90
40	Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH ₂	1088.32	1088	95
	Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1147.35	1147.4	97.5
45	Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1135.33	1135.1	99
50	Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1163.39	1163.4	99
	Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1149.36	1149.2	99
55	Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1107.28	1107	98.9

(continued)

	Compound	Calculated Molecular Weight	Experimental Molecular Weight	Purity
5	Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1107.28	1107.4	99
10	Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1123.32	1123.2	99
	Ac-D-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1163.39	1163.6	94
15	Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1143.31	1143.3	96.9
	Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1143.31	1143.3	96.5
20	Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1135.33	1135.4	99
25	n-Butyryl-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1177.41	1177.5	88.6
	Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1157.34	1157.2	70
30	Ac-β-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1141.36	1141.2	89
35	Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1081.24	1080.9	92.5
	Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH ₂	1135.33	1135.2	85
40	Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH ₂	1149.36	1149.1	87
	Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH ₂	1095.27	1095.4	98.6
45	Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH ₂	1109.3	1109.2	93.8
50	Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH ₂	1129.29	1129.2	81.9
	Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-D-Ala-Lys)-NH ₂	1095.27	1095.3	97
55	Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-β-Ala-Lys)-NH ₂	1095.27	1095.3	82

(continued)

	Compound	Calculated Molecular Weight	Experimental Molecular Weight	Purity
5	Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH ₂	1109.3	1109.1	99
	Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH ₂	1137.35	1137.4	98
10	Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH ₂	1123.32	1123.3	97.3
15	Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH ₂	1102.35	1102	99
	Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH ₂	1088.32	1087.8	97
20	Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH ₂	1116.38	1116.2	99
25	Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-NH ₂	1074.3	1073.8	99.9
	Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-NH ₂	1074.3	1073.8	99.9
30	Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH ₂	1124.36	1123.6	96.1
	Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH ₂	1135.38	1134.5	99.1
35	Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH ₂	1135.38	1134.6	94.8
40	nButanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH ₂	1113.37	1112.6	95.7
	nButanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	1102.35	1101.5	99.9
45	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH ₂	1085.32	1084.4	97.7
50	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-Nal-Cys)-NH ₂	1085.32	1084.5	96.6
	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Bal-Cys)-NH ₂	1091.35	1090.4	96.2
55	Ac-Nle-c(Cys-D-Glu-His-D-Phe-Arg-Trp-Cys)-NH ₂	1132.33	1131.5	99.9

(continued)

	Compound	Calculated Molecular Weight	Experimental Molecular Weight	Purity
5	Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-D-Ala-Lys)-NH ₂	1095.27	1094.6	99.9
10	Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH ₂	1141.41	1140.5	95.6
	Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	1102.35	1101.6	99.9
15	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH ₂	1102.35	1101.6	99.9
	Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH ₂	1130.4	1129.6	99.9
20	D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH ₂	1181.41	1181.7	96.9
25	D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH ₂	1211.43	1211.7	97.1
	D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH ₂	1204.44	1204.6	99
30	D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH ₂	1225.46	1225.7	97
35	D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH ₂	1218.47	1218.8	99
	D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH ₂	1262.52	1263	99
40	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH ₂	1131.35	1131.2	96.8
45	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH ₂	1145.37	1145.3	96.4
	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH ₂	1145.37	1145.2	98.2
50	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	1159.4	1159.2	95.1
	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH ₂	1173.43	1173.3	96.8
55	Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH ₂	1060.31	1060.3	98.5

(continued)

	Compound	Calculated Molecular Weight	Experimental Molecular Weight	Purity
5	Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH ₂	1095.27	1094.7	96.2
10	Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH ₂	1112.32	1111.7	96.5
	Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH ₂	1090.25	1089.6	99.9
15	Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH ₂	1101.27	1100.6	98.3
	Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH ₂	1032.22	1031.5	95.2
20	Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH ₂	1043.24	1042.5	95.6
25	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH ₂	1144.39	1144.6	95.3
	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH ₂	1145.37	1144.6	97.3
30	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	1158.41	1158.6	96.5
35	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH	1103.33	1103	99.9
	Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH ₂	1088.32	1087.6	99.9
40	Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH ₂	1102.35	1101.7	99.9
45	Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH ₂	1116.38	1115.7	99.9
	Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH ₂	1116.38	1115.8	97.4
50	Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH ₂	1116.38	1115.5	96.5
	Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH ₂	1156.44	1155.6	96.4
55	Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	1116.38	1115.7	95

(continued)

	Compound	Calculated Molecular Weight	Experimental Molecular Weight	Purity
5	Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH ₂	1116.38	1115.5	99.9
10	Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH ₂	1144.43	1144	99.9
	Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	1088.32	1088	96.7
15	Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	1128.39	1128.4	95.8
20	Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	1088.32	1088.4	95
	Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	1122.34	1122	95.2
25	Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	1074.3	1074.6	95.4
	Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	1172.4	1172.2	95.2
30	Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	1046.29	1046.4	97.6
35	Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	1080.3	1080	95.8
	Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	1099.35	1099.6	96.6
40	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH	1075.28	1075.2	99.9
45	Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH ₂	1088.32	1088	95.8
	Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH ₂	1183.4	1182.85	99.9
50	Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH ₂	1145.33	1145	99.99
	Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-βAla-Lys)-NH ₂	1145.33	1145	99.99
55	Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH ₂	1138.38	1137.8	99.99

(continued)

Compound	Calculated Molecular Weight	Experimental Molecular Weight	Purity
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH ₂	1166.44	1166	99
Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH ₂	1207.4	1206.9	99
Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH ₂	1199.42	1198.8	100
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	1117.3	1116.9	95.10
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	1117.33	1116.8	99.2
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH ₂	1145.38	1144.9	96.4
Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH ₂	1159.41	1158.9	99.9
Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH ₂	1159.41	1159.1	99
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH ₂	1145.38	1145.1	99
Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH ₂	1138.3	1138.0	98.0
Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH ₂	1138.3	1138.1	99.0

Table 1B

Compound	Calculated Molecular Weight	Experimental Molecular Weight	Purity
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH ₂	1167.39	1167.40	99.9

Example 3: *In vitro* studies

[0120] Compounds herein can be and were tested for activity as ligands of one or more of the melanocortin receptors according to the following procedures. One skilled in the art would know that procedures similar to those described herein may be used to assay the binding activities of the compounds herein to melanocortin receptor molecules.

Radioligand Binding Assays

[0121] Cellular membranes used for the *in vitro* receptor binding assays were obtained from transgenic CHO-K1 cells stably expressing hMC-R receptor subtypes 1, 3, 4 or 5. The CHO-K1 cells expressing the desired hMC-R receptor type were sonicated (Branson® setting 7, approximately 30 sec) in ice-cold 50 mM Tris-HCl at pH 7.4 and then centrifuged

at 39,000 g for 10 minutes at approximately 4°C. The pellets were resuspended in the same buffer and centrifuged at 50,000 g for 10 minutes at approximately 4°C. The washed pellets containing the cellular membranes were stored at approximately - 80°C.

[0122] Competitive inhibition of [¹²⁵I](Tyr²)-(Nle⁴-D-Phe⁷) α -MSH([¹²⁵I]-NDP- α -MSH, Amersham Biosciences®) binding was carried out in polypropylene 96 well plates. Cell membranes (1-10 μ g protein/well) prepared as described above were incubated in 50 mM Tris-HCl at pH 7.4 containing 0.2% bovine serum albumin (BSA), 5 mM MgCl₂, 1 mM CaCl₂ and 0.1 mg/mL bacitracin, with increasing concentrations of the test compound and 0.1-0.3 nM [¹²⁵I]-NDP- α -MSH for approximately 90-120 minutes at approximately 37°C. Bound [¹²⁵I]-NDP- α -MSH ligand was separated from free [¹²⁵I]-NDP- α -MSH by filtration through GF/C glass fiber filter plates (Unifilter®; Packard) presoaked with 0.1 % (w/v) poly-ethylenimine (PEI), using a Packard Filtermate® harvester. Filters were washed three times with 50 mM Tris-HCl at pH 7.4 at a temperature of approximately 0-4°C and then assayed for radioactivity using a Packard Topcount® scintillation counter. Binding data were analyzed by computer-assisted non-linear regression analysis (XL fit; IDBS).

[0123] A selection of the compounds herein was tested using the above-discussed assay and the binding constants (K_i in nM) are reported in Tables 2A, 2B and 2C.

[0124] TABLES 2A, 2B and 2C - Radioligand Binding Assay Data for Selected Compounds

Table 2A

Compound	Ki hMC1-R	Ki hMC3-R	Ki hMC4-R	Ki hMC5-R	Ki hMC1-R/MC4-R
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	3.87	10.1	2.09	430	1.9
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	4.01	12.1	1.76	352	2.3
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH ₂	8.29	13.3	2.78	816	3.0
Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH ₂	3.93	172	11.0	538	0.36
Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH ₂	1.81	20.5	4.57	502	0.4
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH ₂	9.67	22.0	4.2	1900	2.3
Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH ₂	0.79	45.5	1.21	493	0.6
Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH ₂	0.68	20.7	1.01	783	0.7

Table 2B

Compound	Ki hMC1-R	Ki hMC3-R	Ki hMC4-R	Ki hMC5-R	Ki hMC1-R/MC4-R
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH ₂	114	63.9	3.07	1657	37.1
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	11	26	7.6	1800	1.4

(continued)

	Compound	Ki hMC1-R	Ki hMC3-R	Ki hMC4-R	Ki hMC5-R	Ki hMC1-R/MC4-R
5	D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH ₂	0.05	9.3	1.1	2.9	0.0
	Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH ₂	0.07	4.1	0.85	8.8	0.1
10	Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH ₂	0.12	10	0.43	0.42	0.3
	Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	0.05	1.3	0.47	0.2	0.1
15	Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH ₂	0.0996	9318	0.617	10.9	0.16
20	Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH ₂	.0132	16.1	1.23	0.359	0.11
	D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH ₂	0.207	43.2	2.58	344	0.08
25	D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH ₂	0.420	106	4.75	1260	0.09
30	Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH ₂	0.0951	9.33	0.894	13.4	0.11
	Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH ₂	0.999	300	11.1	431	0.09
35	Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	0.106	11.8	1.49	110	0.07
40	Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	0.0506	9.89	1.04	16.3	0.05
	Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	0.884	223	22.5	609	0.04
45	Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	0.721	93.5	56.0	747	0.01
50	Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	0.227	14.5	2.99	164	0.08
	Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	0.277	25.2	3.37	203	0.08
55	Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-NH ₂	0.323	14.1	1.96	24.0	0.16

(continued)

	Compound	Ki hMC1-R	Ki hMC3-R	Ki hMC4-R	Ki hMC5-R	Ki hMC1-R/MC4-R
5	Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	34.1	118	17.0	5560	2.01
10	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH ₂	29.1	22.8	3.84	2550	7.58
	D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH ₂	0.442	123	10.3	521	0.04
15	D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH ₂	5.80	3370	583	1130	0.01
20	D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH ₂	0.0567	31.4	14.7	9.27	0
	D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH ₂	1.68	1260	172	1220	0.01
25	D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH ₂	0.128	85.6	36.9	38.0	0
30	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH ₂	0.352	149	3.01	339	0.12
	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH ₂	3.93	876	48.0	4940	0.08
35	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH ₂	0.995	287	4.80	766	0.21
40	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	0.848	184	3.76	956	0.23
	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH ₂	1.10	228	7.58	859	0.15
45	Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH ₂	0.659	98.9	2.55	4.19	0.26
	Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH ₂	4.12	445	50.6	4300	0.08
50	Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH ₂	111	1710	47.7	694	2.33
55	Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH ₂	262	2500	96.4	1460	2.72

(continued)

	Compound	Ki hMC1-R	Ki hMC3-R	Ki hMC4-R	Ki hMC5-R	Ki hMC1-R/MC4-R
5	Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH ₂	199	5990	96.7	> 10000	2.06
10	Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH ₂	132	4560	40.7	8810	3.24
	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH ₂	9.12	1130	22.1	2860	0.41
15	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH ₂	1.00	227	5.55	496	0.18
	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	0.536	169	3.12	358	0.17
20	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH	32.1	330	17.4	165	1.84
25	Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH ₂	10.6	41.1	7.69	54.9	1.38
	Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH ₂	13.0	104	10.1	40	1.29
30	Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH ₂	4.28	38.5	9.0	12.5	0.48
35	Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH ₂	1.60	6.82	4.13	5.57	0.39
	Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH ₂	12.0	85.8	11.2	40	1.07
40	Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH ₂	0.353	2.08	1.41	0.857	0.25
45	Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	0.537	86.1	5.89	2.56	0.09
	Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH ₂	0.744	178	3.51	2.69	0.21
50	Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	0.216	17.4	0.995	0.486	0.22
	Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	0.107	9.11	0.884	0.354	0.12
55	Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	0.148	13.9	1.06	0.423	0.14

(continued)

	Compound	Ki hMC1-R	Ki hMC3-R	Ki hMC4-R	Ki hMC5-R	Ki hMC1-R/MC4-R
5	Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	0.254	18.5	2.13	0.714	0.12
10	Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	0.256	29.9	1.98	0.864	0.13
	Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	0.560	39.2	2.94	2.73	0.19
15	Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	0.186	15.2	4.93	0.537	0.04
	Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	21.1	151	10.4	92.6	2.03
20	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH	30.7	152	15.6	114	1.97
25	Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH ₂	5.20	150	138	20.3	0.04
	Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH ₂	4.89	290	21.3	11.1	0.23
30	Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH ₂	25.5	3.82	7.61	102	3.35
35	Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH ₂	32.5	5.85	2.53	94.6	12.85
	Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH ₂	22.2	12.7	16.6	125	1.34
40	Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH ₂	1.17	1.56	0.277	3.24	4.22
45	Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH ₂	0.648	2.78	0.329	1.4	1.97
	Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH ₂	0.393	1.86	0.375	1.11	1.05
50	Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH ₂	0.333	2.91	0.998	0.366	0.33
	Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH ₂	0.461	2.45	0.931	1.37	0.50
55	Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH ₂	0.576	3.98	2.82	3.91	0.20

Table 2C

Compound	Ki hMC1-R	Ki hMC3-R	Ki hMC4-R	Ki hMC5-R	Ki hMC1-R/MC4-R
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH ₂	17.9	1.68	0.256	23.4	69.9

cyclic AMP Bioassay

[0125] Intracellular cyclic AMP (cAMP) levels were determined by an electrochemiluminescence (ECL) assay (Meso Scale Discovery®, Gaithersburg, MD; referred to hereinafter as MSD). CHO-K1 cells stably expressing the hMC receptor subtypes were suspended in RMPI 1640® assay buffer (RMPI 1640 buffer contains 0.5 mM isobutylmethylxanthine (IBMX), and 0.2% protein cocktail (MSD blocker A)). Transgenic CHO-K1 cells stably expressing hMC receptor subtypes 1, 3, 4 or 5 were dispensed at a density of approximately 7,000 cells/well in 384-well Multi-Array® plates (MSD) containing integrated carbon electrodes and coated with anti-cAMP antibody. Increasing concentrations of the test compounds were added and the cells were incubated for approximately 40 minutes at approximately 37°C. Following this incubation, lysis buffer (HEPES-buffered saline solution with MgCl₂ and Triton X-100® at pH 7.3) containing 0.2% protein cocktail and 2.5 nM TAG™ ruthenium-labeled cAMP (MSD) was added and the cells were incubated for approximately 90 minutes at room temperature. At the end of the second incubation period read buffer (Tris-buffered solution containing an ECL co-reactant and Triton X-100 at pH 7.8) was added and the cAMP levels in the cell lysates were immediately determined by ECL detection with a Sector Imager 6000 reader® (MSD). Data were analyzed using a computer-assisted non-linear regression analysis (XL fit; IDBS) and reported as either an EC₅₀ value or a K_b value.

[0126] EC₅₀ represents the concentration of an agonist compound needed to obtain 50% of the maximum reaction response, e.g., 50% of the maximum level of cAMP as determined using the assay described above. The K_b value reflects the potency of an antagonist and is determined by Schild analysis. In brief, concentration-response curves of an agonist are carried out in the presence of increasing concentrations of an antagonist. The K_b value is the concentration of antagonist which would produce a 2-fold shift in the concentration-response curve for an agonist. It is calculated by extrapolating the line on a Schild plot to zero on the y-axis.

[0127] A selection of compounds was tested using the above-discussed assays and the results are reported in Tables 3A, 3B, 3C, and 3D.

[0128] TABLES 3A, 3B, 3C, and 3D - cAMP Bioassay Data for Selected Compounds

Table 3A

Compound	EC ₅₀ hMC1-R	EC ₅₀ hMC3-R	EC ₅₀ hMC4-R	EC ₅₀ hMC5-R	EC ₅₀ hMC1-R/MC4-R
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	5.79	5.25	0.313	1630	18.0
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	6.17	5.6	0.397	1020	16.0
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH ₂	26.5	10.5	0.493	2440	54.0
Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH ₂	8.43	32.4	0.959	2140	9.0
Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH ₂	4.23	8.09	0.719	23.2	6.0

(continued)

Compound	EC ₅₀ hMC1-R	EC ₅₀ hMC3-R	EC ₅₀ hMC4-R	EC ₅₀ hMC5-R	EC ₅₀ hMC1-R/MC4-R
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH ₂	48.3	13.3	0.79	10000	61.0
Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH ₂	1.48	5.76	0.078	297	19.0
Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH ₂	1.39	2.89	0.055	467	25.0
ND = not determined					

Table 3B

Compound	EC ₅₀ hMC1-R	EC ₅₀ hMC3-R	EC ₅₀ hMC4-R	EC ₅₀ hMC5-R	EC ₅₀ hMC1-R/MC4-R
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	2.4	0.33	0.078	420	31
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH ₂	0.35	1.1	0.11	0.37	3
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH ₂	0.31	0.27	0.018	3.1	17
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH ₂	0.28	0.24	0.028	3.9	10
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH ₂	0.37	0.1	0.021	1.7	18
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH ₂	0.834	0.145	0.128	2.79	6.52
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH ₂	0.76	0.199	0.0492	1.73	15.45
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	3.26	0.189	0.0949	30.2	34.35

(continued)

Compound	EC ₅₀ hMC1-R	EC ₅₀ hMC3-R	EC ₅₀ hMC4-R	EC ₅₀ hMC5-R	EC ₅₀ hMC1-R/MC4-R
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	1.37	0.628	0.131	3.48	10.46
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH ₂	2.27	3.32	7.24	415	0.31
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂	ND	1.89	0.531	ND	ND
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH ₂	14.3	2.03	0.183	2240	78.14
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH ₂	0.345	2.71	5376	2.38	0.06
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH ₂	0.685	81.8	86.9	31.8	0.01
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH ₂	0.931	3.22	1.65	>10000	0.56
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH ₂	3.24	0.465	0.0915	78.5	35.41
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH ₂	0.819	0.541	0.453	45.3	1.81
ND = not determined					

Table 3C

Compound	EC50 hMC1-R	Kb hMC3-R	Kb MC4-R	EC50 hMC5-R
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH ₂	17.6	12.4	38.8	11.8
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH ₂	0.619	2.98	0.109	0.189

(continued)

Compound	EC50 hMC1-R	Kb hMC3-R	Kb MC4-R	EC50 hMC5-R
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH ₂	0.913	0.536	0.346	0.489
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH ₂	0.231	18.4	0.782	0.153
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH ₂	0.581	10.8	0.967	0.126
Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH ₂	0.413	9.32	0.824	0.307
Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH ₂	1.27	3.02	0.442	0.736
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH ₂	383	61.5	53.6	2842

Table 3D

Compound	EC50 hMC1-R	Kb hMC3-R	Kb MC4-R	EC50 hMC5-R
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH ₂	193	5.72	1.58	1111

Example 4: *In vivo* studies

[0129] Compounds herein can be and were tested for an effect upon food intake and/or body weight according to the following procedures. One skilled in the art would know that procedures similar to those described herein may be used to assay the effect of the compounds upon food intake and/or body weight.

[0130] Ligand compounds activating melanocortin receptors tested in the *in vivo* studies were as follows (Table 4):

Table 4

Ligand Code	Structure
Compound A	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arp-Trp-Cys)-NH ₂
Compound B	Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arp-Trp-Pen)-NH ₂
Compound C	Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH ₂
Compound D	D-Phe-c(Cys-His-D-(Et)Tyr-Arp-Trp-β-Ala-D-Cys)-Thr-NH ₂
Compound E	Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH ₂
Compound F	Ac-D-Arp-c(Cys-D-Ala-His-D-Phe-Arp-Trp-Cys)-NH ₂
Compound G	Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH ₂

Acute feeding experiments (fasting)

[0131] Male Sprague Dawley rats (250g) were housed in individual cages and maintained under 12:12 hour light:dark conditions. The rats were fasted for 18 hours prior to the start of the experiment with water available *ad libitum*. At time 0, the rats were injected subcutaneously (sc) with selected compounds at doses of either 500 or 100 nmole/kg, or with vehicle, and were provided with food. Individual food consumption was measured at about 1, 2, 3, 4, 5 and 6 hours after injection. Data for selected compounds are reported in Figures 1A and 1B.

Acute feeding experiments (non fasting)

[0132] Male Sprague Dawley rats (250g) are housed in individual cages and maintained under 12:12 hour light:dark conditions. Food and water is available *ad libitum* throughout the experiment. At time 0, the rats are injected sc with compound at doses of either 500 or 100 nmole/kg, or with vehicle. Individual food consumption is measured at about 1, 2, 3, 4, 5 and 6 hours after injection.

Chronic feeding experiments

[0133] Male Sprague Dawley rats (250g) were housed in individual cages and maintained under 12:12 hour light:dark conditions with both food and water available *ad libitum*. The rats were injected sc 3x/day (approximately 0800 hour, 1200 hour, and 1600 hour) with compound at various doses or with vehicle for 7 days. Individual body weight and food consumption were measured daily. Data for selected compounds are reported in Figures 2A and 2B, Figures 3A and 3B, and Figures 4A and 4B.

Administration and Use

[0134] The peptides herein can be provided in the form of pharmaceutically acceptable salts. Examples of such salts include, but are not limited to, those formed with organic acids (e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid), inorganic acids (e.g., hydrochloric acid, sulfuric acid, or phosphoric acid), and polymeric acids (e.g., tannic acid, carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of polylactic-glycolic acids). A typical method of making a salt of a peptide herein is well known in the art and can be accomplished by standard methods of salt exchange. Accordingly, the TFA salt of a peptide herein (the TFA salt results from the purification of the peptide by using preparative HPLC, eluting with TFA containing buffer solutions) can be converted into another salt, such as an acetate salt, by dissolving the peptide in a small amount of 0.25 N acetic acid aqueous solution. The resulting solution is applied to a semi-prep HPLC column (Zorbax®, 300 SB, C-8). The column is eluted with: (1) 0.1N ammonium acetate aqueous solution for 0.5 hours; (2) 0.25N acetic acid aqueous solution for 0.5 hours; and (3) a linear gradient (20% to 100% of solution B over 30 minutes) at a flow rate of 4 ml/min (solution A is 0.25N acetic acid aqueous solution; solution B is 0.25N acetic acid in acetonitrile/water, 80:20). The fractions containing the peptide are collected and lyophilized to dryness.

[0135] As is well known to those skilled in the art, the known and potential uses of peptides with melanocortin receptor (MC-R) agonist or antagonist activity is varied and multitudinous, thus the administration of the compounds herein for purposes of eliciting an agonist effect can have the same effects and uses as melanocortin itself.

[0136] Accordingly, described herein are pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of formula (I) in association with a pharmaceutically acceptable carrier.

[0137] The dosage of active ingredient in the compositions herein may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. In general, an effective dosage for the activities herein is in the range of 1×10^{-7} to 200 mg/kg/day, preferably 1×10^{-4} to 100 mg/kg/day which can be administered as a single dose or divided into multiple doses.

[0138] The compounds herein can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.

[0139] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

[0140] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents,

compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.

[0141] Preparations herein for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. Preparations may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. Preparations can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water or some other sterile injectable medium immediately before use.

[0142] Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as cocoa butter or a suppository wax.

[0143] Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.

[0144] Further, a compound herein can be administered in a sustained release composition such as those described in the following patents and patent applications. U.S. Patent No. 5,672,659 teaches sustained release compositions comprising a bioactive agent and a polyester. U.S. Patent No. 5,595,760 teaches sustained release compositions comprising a bioactive agent in a gelable form. U.S. Patent No. 5,821,221 teaches polymeric sustained release compositions comprising a bioactive agent and chitosan. U.S. Patent No. 5,916,883 teaches sustained release compositions comprising a bioactive agent and cyclodextrin.

SEQUENCE LISTING

[0145]

<110> IPSEN PHARMA

<120> MELANOCORTIN RECEPTOR LIGANDS

<130> P120298EPD4

<141> 2006-07-10

<150> US 60/748850

<151> 2005-12-09

<150> US 60/697779

<151> 2005-07-08

<160> 61

<170> PatentIn version 3.3

<210> 1

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Melanocortin receptor ligand

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa = Nle modified with acyl (Ac)

<220>

<221> DOMAIN

<222> (2)..(8)

5

<223> Cyclic

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa = D-Phe

10

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa = beta-Ala or 1-amino-1-cyclohexanecarboxylic acid (A6c)

15

<220>

<221> MOD_RES

<222> (8)..(8)

<223> AMIDATION

20

<400> 1

Xaa Asp His Xaa Arg Trp Xaa Lys

1 5

25

<210> 2

<211> 8

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Melanocortin receptor ligand

35

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa = Nle modified with acyl (Ac)

40

<220>

<221> DOMAIN

<222> (2)..(8)

<223> Cyclic

45

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa = D-Phe

50

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa = 6-aminohexanoic acid (Ahx) or 5-aminopentanoic acid (Apn)

55

<220>

<221> MOD_RES

<222> (8)..(8)

<223> AMIDATION

<400> 2

		Xaa	Cys	His	Xaa	Arg	Trp	Xaa	Cys
		1				5			
5		<210> 3							
		<211> 9							
		<212> PRT							
		<213> Artificial Sequence							
10		<220>							
		<223> Melanocortin receptor ligand							
15		<220>							
		<221> MISC_FEATURE							
		<222> (1)..(1)							
		<223> Xaa = D-Phe							
20		<220>							
		<221> DOMAIN							
		<222> (2)..(8)							
		<223> Cyclic							
25		<220>							
		<221> MISC_FEATURE							
		<222> (4)..(4)							
		<223> Xaa = D-Phe							
30		<220>							
		<221> MISC_FEATURE							
		<222> (7)..(7)							
		<223> Xaa = Ala, beta-Ala or 4-aminobutyric acid (Gaba)							
35		<220>							
		<221> MISC_FEATURE							
		<222> (8)..(8)							
		<223> Xaa = D-Cys							
40		<220>							
		<221> MOD_RES							
		<222> (9)..(9)							
		<223> AMIDATION							
		<400> 3							
45		Xaa	Cys	His	Xaa	Arg	Trp	Xaa	Xaa
		1				5			Thr
50		<210> 4							
		<211> 8							
		<212> PRT							
		<213> Artificial Sequence							
55		<220>							
		<223> Melanocortin receptor ligand							
		<220>							
		<221> MISC_FEATURE							
		<222> (1)..(1)							
		<223> Xaa = Nle modified with acyl (Ac)							

	<220>	
	<221> DOMAIN	
	<222> (2)..(8)	
5	<223> Cyclic	
	<220>	
	<221> MISC_FEATURE	
	<222> (4)..(4)	
10	<223> Xaa = D-Phe	
	<220>	
	<221> MISC_FEATURE	
	<222> (7)..(7)	
15	<223> Xaa = 5-aminopentanoic acid (Apn)	
	<220>	
	<221> MOD_RES	
	<222> (8)..(8)	
20	<223> AMIDATION	
	<400> 4	
		Xaa Asp His Xaa Arg Trp Xaa Lys
25		1 5
	<210> 5	
	<211> 8	
	<212> PRT	
	<213> Artificial Sequence	
30	<220>	
	<223> Melanocortin receptor ligand	
	<220>	
35	<221> MISC_FEATURE	
	<222> (1)..(1)	
	<223> Xaa = 1-amino-1-cyclohexanecarboxylic acid (A6c) modified with acyl (Ac)	
	<220>	
40	<221> DOMAIN	
	<222> (2)..(8)	
	<223> Cyclic	
	<220>	
45	<221> MISC_FEATURE	
	<222> (4)..(4)	
	<223> Xaa = D-Phe	
	<220>	
50	<221> MISC_FEATURE	
	<222> (7)..(7)	
	<223> Xaa = 4-aminobutyric acid (Gaba)	
	<220>	
55	<221> MOD_RES	
	<222> (8)..(8)	
	<223> AMIDATION	

<400> 5	
5	Xaa Asp His Xaa Arg Trp Xaa Lys
	1 5
	<210> 6
	<211> 8
	<212> PRT
10	<213> Artificial Sequence
	<220>
	<223> Melanocortin receptor ligand
	<220>
	<221> MISC_FEATURE
15	<222> (1)..(1)
	<223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal), beta-cyclohexylAla (Cha) or Nle, all modified with acyl (Ac)
	<220>
	<221> DOMAIN
20	<222> (2)..(8)
	<223> Cyclic
	<220>
	<221> MISC_FEATURE
25	<222> (4)..(4)
	<223> Xaa = D-Phe
	<220>
	<221> MISC_FEATURE
30	<222> (7)..(7)
	<223> Xaa = 4-aminobutyric acid (Gaba)
	<220>
	<221> MOD_RES
35	<222> (8)..(8)
	<223> AMIDATION
	<400> 6
40	Xaa Asp His Xaa Arg Trp Xaa Lys
	1 5
	<210> 7
	<211> 8
	<212> PRT
45	<213> Artificial Sequence
	<220>
	<223> Melanocortin receptor ligand
	<220>
	<221> MISC_FEATURE
50	<222> (1)..(1)
	<223> Xaa = Nle modified with acyl (Ac)
	<220>
	<221> DOMAIN
55	

5

<222> (2)..(8)
<223> Cyclic

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = D-Ala, beta-Ala, 4-aminobutyric acid (Gaba), alpha-aminoisobutyric acid (Aib) or Gly

10

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = D-Phe

15

<220>
<221> MOD_RES
<222> (8)..(8)
<223> AMIDATION

20

<400> 7

Xaa Cys Xaa His Xaa Arg Trp Cys
1 5

25

<210> 8
<211> 8
<212> PRT
<213> Artificial Sequence

30

<220>
<223> Melanocortin receptor ligand

35

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Nle modified with acyl (Ac)

40

<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

45

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = D-Cys

50

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = Ala, D-Ala, beta-Ala, 4-aminobutyric acid (Gaba), alpha-aminoisobutyric acid (Aib) or Gly

55

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = D-Phe

<220>
<221> MOD_RES

	<222> (8)..(8)	
	<223> AMIDATION	
5	<400> 8	
	Xaa Xaa Xaa His Xaa Arg Trp Cys	
	1 5	
10	<210> 9	
	<211> 8	
	<212> PRT	
	<213> Artificial Sequence	
15	<220>	
	<223> Melanocortin receptor ligand	
20	<220>	
	<221> MISC_FEATURE	
	<222> (1)..(1)	
	<223> Xaa = Nle modified with acyl (Ac)	
25	<220>	
	<221> DOMAIN	
	<222> (2)..(8)	
	<223> Cyclic	
30	<220>	
	<221> MISC_FEATURE	
	<222> (3)..(3)	
	<223> Xaa = D-Ala, beta-Ala, 4-aminobutyric acid (Gaba), alpha-aminoisobutyric acid (Aib) or Gly	
35	<220>	
	<221> MISC_FEATURE	
	<222> (5)..(5)	
	<223> Xaa = D-Phe	
40	<220>	
	<221> MISC_FEATURE	
	<222> (8)..(8)	
	<223> Xaa = D-Cys	
45	<220>	
	<221> MOD_RES	
	<222> (8)..(8)	
	<223> AMIDATION	
	<400> 9	
50	Xaa Cys Xaa His Xaa Arg Trp Xaa	
	1 5	
55	<210> 10	
	<211> 8	
	<212> PRT	
	<213> Artificial Sequence	
	<220>	
	<223> Melanocortin receptor ligand	

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Nle modified with acyl (Ac)
5

<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic
10

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = D-Cys
15

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = Ala, D-Ala, beta-Ala, 4-aminobutyric acid (Gaba) or alpha-aminoisobutyric acid (Aib)
20

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = D-Phe
25

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa = D-Cys
30

<220>
<221> MOD_RES
<222> (8)..(8)
<223> AMIDATION
35

<400> 10

Xaa Xaa Xaa His Xaa Arg Trp Xaa
1 5
40

<210> 11
<211> 8
<212> PRT
<213> Artificial Sequence
45

<220>
<223> Melanocortin receptor ligand

<220>
50

<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = octahydroindole-2-carboxylic acid (Oic), cyclohexylGly (Chg),
homo-cyclohexylAla (hCha), D-betacyclohexylAla (D-Cha), nipecotic acid (Nip),
55 homo-Pro (hPro), homo-Leu (hLeu), Phe, D-Phe, D-cyclohexylGly (D-Chg),homo-Phe (hPhe),
beta-homoMet (beta-hMet) or 4-aminobutyric acid (Gaba), all modified with acyl (Ac)

<220>

	<221> DOMAIN <222> (2)..(8) <223> Cyclic
5	<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
10	<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
15	<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
20	<400> 11
	Xaa Asp His Xaa Arg Trp Xaa Lys 15
25	<210> 12 <211> 8 <212> PRT <213> Artificial Sequence
30	<220> <223> Melanocortin receptor ligand
35	<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = beta-cyclohexylAla (Cha) modified with n-butanoyl
40	<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
45	<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
50	<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
55	<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
	<400> 12

		Xaa	Asp	His	Xaa	Arg	Trp	Xaa	Lys
		1				5			
5		<210>	13						
		<211>	8						
		<212>	PRT						
		<213>	Artificial Sequence						
10		<220>							
		<223>	Melanocortin receptor ligand						
15		<220>							
		<221>	MISC_FEATURE						
		<222>	(1)..(1)						
		<223>	Xaa = beta-cyclohexylAla (Cha), homo-cyclohexylAla (hCha), Leu, homo-Leu (hLeu) or Phe, all modified with acyl (Ac)						
20		<220>							
		<221>	DOMAIN						
		<222>	(2)..(8)						
		<223>	Cyclic						
25		<220>							
		<221>	MISC_FEATURE						
		<222>	(4)..(4)						
		<223>	Xaa = D-Phe						
30		<220>							
		<221>	MISC_FEATURE						
		<222>	(6)..(6)						
		<223>	Xaa = D-Trp						
35		<220>							
		<221>	MOD_RES						
		<222>	(8)..(8)						
		<223>	AMIDATION						
40		<400>	13						
		Xaa	Asp	His	Xaa	Arg	Xaa	Ala	Lys
		1				5			
45		<210>	14						
		<211>	8						
		<212>	PRT						
		<213>	Artificial Sequence						
50		<220>							
		<223>	Melanocortin receptor ligand						
55		<220>							
		<221>	MISC_FEATURE						
		<222>	(1)..(1)						
		<223>	Xaa = Nle modified with acyl (Ac)						
		<220>							
		<221>	DOMAIN						
		<222>	(2)..(8)						

	<223> Cyclic	
5	<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe	
10	<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Trp	
15	<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = D-Ala, beta-Ala, 4-aminobutyric acid (Gaba), 7-aminoheptanoic acid (Aha) or 5-aminopentanoic acid (Apn)	
20	<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION	
25	<400> 14	
		Xaa Asp His Xaa Arg Xaa Xaa Lys 1 5
30	<210> 15 <211> 8 <212> PRT <213> Artificial Sequence	
35	<220> <223> Melanocortin receptor ligand	
40	<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)	
45	<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic	
50	<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe	
55	<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Trp	
	<220> <221> MISC_FEATURE	

<222> (7)..(7)
<223> Xaa = 5-aminopentanoic acid (Apn), 4-aminobutyric acid (Gaba), 6-aminohexanoic acid (Ahx), beta-Ala, D-Ala

5
<220>
<221> MOD_RES
<222> (8)..(8)
<223> AMIDATION

10
<400> 15

Xaa Cys His Xaa Arg Xaa Xaa Cys
1 5

15
<210> 16
<211> 8
<212> PRT
<213> Artificial Sequence

20
<220>
<223> Melanocortin receptor ligand

25
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Nle modified with acyl (Ac)

30
<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

35
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = D-Ala

40
<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)

45
<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa = Trp, beta-(2-naphthyl)Ala (2-Nal) or beta-(1-naphthyl)Ala (1-Nal)

50
<220>
<221> MOD_RES
<222> (8)..(8)
<223> AMIDATION

<400> 16

55
Xaa Cys Xaa His Xaa Arg Xaa Cys
1 5

<210> 17
<211> 8

<212> PRT
<213> Artificial Sequence

<220>
<223> Melanocortin receptor ligand

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Nle modified with n-butanoyl

<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = D-Ala

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = D-Phe

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa = beta-(2-naphthyl)Ala (2-Nal) or Trp

<220>
<221> MOD_RES
<222> (8)..(8)
<223> AMIDATION

<400> 17

Xaa Cys Xaa His Xaa Arg Xaa Cys
15

<210> 18
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Melanocortin receptor ligand

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Nle modified with acyl (Ac)

<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

5

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = D-Ala

10

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = D-Phe

15

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa = beta-(2-naphthyl)Ala (2-Nal), beta-(1-naphthyl)Ala (1-Nal) or 3-benzothierylAla (Bal)

20

<220>
<221> MOD_RES
<222> (8)..(8)
<223> AMIDATION

25

Xaa Cys Xaa His Xaa Arg Xaa Cys
1 5

30

<210> 19
<211> 8
<212> PRT
<213> Artificial Sequence

35

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Nle modified with acyl (Ac)

40

<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

45

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = D-Phe

50

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa = D-Ala

55

<220>
<221> MOD_RES
<222> (8)..(8)
<223> AMIDATION

<400> 19

5

Xaa Asp His Xaa Arg Trp Xaa Lys

15

<210> 20

<211> 8

<212> PRT

<213> Artificial Sequence

10

<220>

<223> Melanocortin receptor ligand

15

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa = Nle modified with acyl (Ac)

20

<220>

<221> DOMAIN

<222> (2)..(8)

<223> Cyclic

25

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa = D-Ala

30

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> Xaa = D-beta-2-naphthylAla (D-2-Nal)

35

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa = 3-benzothienylAla (Bal)

40

<220>

<221> MOD_RES

<222> (8)..(8)

<223> AMIDATION

45

<400> 20

Xaa Cys Xaa His Xaa Arg Xaa Cys

15

50

<210> 21

<211> 8

<212> PRT

<213> Artificial Sequence

55

<220>

<223> Melanocortin receptor ligand

<220>

<221> MISC_FEATURE

	<222> (1)..(1)	
	<223> Xaa = Nle modified with acyl (Ac)	
5	<220>	
	<221> DOMAIN	
	<222> (2)..(8)	
	<223> Cyclic	
10	<220>	
	<221> MISC_FEATURE	
	<222> (2)..(2)	
	<223> Xaa = penicillamine (Pen)	
15	<220>	
	<221> MISC_FEATURE	
	<222> (3)..(3)	
	<223> Xaa = D-Ala	
20	<220>	
	<221> MISC_FEATURE	
	<222> (5)..(5)	
	<223> Xaa = D-Phe	
25	<220>	
	<221> MOD_RES	
	<222> (8)..(8)	
	<223> AMIDATION	
30	<400> 21	
		Xaa Xaa Xaa His Xaa Arg Trp Cys
		1 5
35	<210> 22	
	<211> 8	
	<212> PRT	
	<213> Artificial Sequence	
40	<220>	
	<223> Melanocortin receptor ligand	
45	<220>	
	<221> MISC_FEATURE	
	<222> (1)..(1)	
	<223> Xaa = Nle modified with acyl (Ac)	
50	<220>	
	<221> DOMAIN	
	<222> (2)..(8)	
	<223> Cyclic	
55	<220>	
	<221> MISC_FEATURE	
	<222> (2)..(2)	
	<223> Xaa = Cys or penicillamine (Pen)	
	<220>	
	<221> MISC_FEATURE	

	<222> (3)..(3)
	<223> Xaa = D-Ala
5	<220>
	<221> MISC_FEATURE
	<222> (5)..(5)
	<223> Xaa = D-Phe
10	<220>
	<221> MISC_FEATURE
	<222> (8)..(8)
	<223> Xaa = penicillamine (Pen)
15	<220>
	<221> MOD_RES
	<222> (8)..(8)
	<223> AMIDATION
20	<400> 22
	Xaa Xaa Xaa His Xaa Arg Trp Xaa
	1 5
25	<210> 23
	<211> 9
	<212> PRT
	<213> Artificial Sequence
30	<220>
	<223> Melanocortin receptor ligand
35	<220>
	<221> MISC_FEATURE
	<222> (1)..(1)
	<223> Xaa = D-Phe
40	<220>
	<221> DOMAIN
	<222> (2)..(8)
	<223> Cyclic
45	<220>
	<221> MISC_FEATURE
	<222> (4)..(4)
	<223> Xaa = D-Phe
50	<220>
	<221> MISC_FEATURE
	<222> (5)..(5)
	<223> Xaa = homo-Arg (hArg)
55	<220>
	<221> MISC_FEATURE
	<222> (7)..(7)
	<223> Xaa = beta-Ala
	<220>
	<221> MISC_FEATURE

<222> (8)..(8)
<223> Xaa = D-Cys

5
<220>
<221> MOD_RES
<222> (9)..(9)
<223> AMIDATION

10
<400> 23

Xaa Cys His Xaa Xaa Trp Xaa Xaa Thr
1 5

15
<210> 24
<211> 9
<212> PRT
<213> Artificial Sequence

20
<220>
<223> Melanocortin receptor ligand

25
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = D-Phe

30
<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

35
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = D-(Et)Tyr

40
<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = Arg or homo-Arg (hArg)

45
<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa = beta-Ala

50
<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa = D-Cys

55
<220>
<221> MOD_RES
<222> (9)..(9)
<223> AMIDATION

<400> 24

		Xaa	Cys	His	Xaa	Xaa	Trp	Xaa	Xaa	Thr
		1				5				
5		<210>	25							
		<211>	9							
		<212>	PRT							
		<213>	Artificial Sequence							
10		<220>								
		<223>	Melanocortin receptor ligand							
15		<220>								
		<221>	MISC_FEATURE							
		<222>	(1)..(1)							
		<223>	Xaa = D-Phe							
20		<220>								
		<221>	DOMAIN							
		<222>	(2)..(8)							
		<223>	Cyclic							
25		<220>								
		<221>	MISC_FEATURE							
		<222>	(4)..(4)							
		<223>	Xaa = D-Phe							
30		<220>								
		<221>	MISC_FEATURE							
		<222>	(6)..(6)							
		<223>	Xaa = 4,4'-biphenylAla (Bip)							
35		<220>								
		<221>	MISC_FEATURE							
		<222>	(7)..(7)							
		<223>	Xaa = beta-Ala							
40		<220>								
		<221>	MISC_FEATURE							
		<222>	(8)..(8)							
		<223>	Xaa = D-Cys							
45		<220>								
		<221>	MOD_RES							
		<222>	(9)..(9)							
		<223>	AMIDATION							
		<400>	25							
50		Xaa	Cys	His	Xaa	Arg	Xaa	Xaa	Xaa	Thr
		1				5				
55		<210>	26							
		<211>	9							
		<212>	PRT							
		<213>	Artificial Sequence							
		<220>								
		<223>	Melanocortin receptor ligand							

5	<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe	
10	<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic	
15	<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe or D-(Et)Tyr	
20	<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = homo-Arg (hArg)	
25	<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 4,4'-biphenylAla (Bip)	
30	<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala	
35	<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys	
40	<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION	
	<400> 26	
45		Xaa Cys His Xaa Xaa Xaa Xaa Xaa Thr 1 5
50	<210> 27 <211> 8 <212> PRT <213> Artificial Sequence	
	<220> <223> Melanocortin receptor ligand	
55	<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle	

5	<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic	
10	<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe	
15	<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn)	
20	<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION	
25	<400> 27 Xaa Cys His Xaa Arg Trp Xaa Cys 1 5	
30	<210> 28 <211> 8 <212> PRT <213> Artificial Sequence	
35	<220> <223> Melanocortin receptor ligand	
40	<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)	
45	<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic	
50	<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala	
55	<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe	
	<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = Trp or 3-benzothiienylAla (Bal)	

5

<220>
<221> MOD_RES
<222> (8)..(8)
<223> AMIDATION

<400> 28

10

Xaa Asp Xaa His Xaa Arg Xaa Lys
1 5

<210> 29
<211> 8
<212> PRT
<213> Artificial Sequence

15

<220>
<223> Melanocortin receptor ligand

20

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Nle modified with acyl (Ac)

25

<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

30

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = D-Ala

35

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = D-Phe

40

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa = penicillamine (Pen) or Cys

45

<220>
<221> MOD_RES
<222> (8)..(8)
<223> C-terminus is the free acid

<400> 29

50

Xaa Cys Xaa His Xaa Arg Trp Xaa
1 5

55

<210> 30
<211> 8
<212> PRT
<213> Artificial Sequence

	<220> <223> Melanocortin receptor ligand
5	<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
10	<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
15	<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-alpha-aminobutyric acid (D-Abu), D-Val, D-Ile, D-Leu, D-tert-Leu (D-Tle) or D-beta-cyclohexylAla (D-Cha)
20	<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
25	<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
30	<400> 30
	Xaa Cys Xaa His Xaa Arg Trp Cys 1 5
35	<210> 31 <211> 8 <212> PRT <213> Artificial Sequence
40	<220> <223> Melanocortin receptor ligand
45	<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
50	<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
55	<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = penicillamine (Pen)
	<220>

	<221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
5	<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
10	<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
15	<400> 31
	Xaa Xaa His Xaa Arg Trp Xaa Cys 1 5
20	<210> 32 <211> 8 <212> PRT <213> Artificial Sequence
25	<220> <223> Melanocortin receptor ligand
30	<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
35	<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
40	<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = Cys or penicillamine (Pen)
45	<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
50	<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
55	<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = penicillamine (Pen)
	<220>

	<221> MOD_RES <222> (8)..(8) <223> AMIDATION
5	<400> 32
	Xaa Xaa His Xaa Arg Trp Xaa Xaa 1 5
10	<210> 33 <211> 8 <212> PRT <213> Artificial Sequence
15	<220> <223> Melanocortin receptor ligand
	<220> <221> MISC_FEATURE
20	<222> (1)..(1) <223> Xaa = Leu, beta-cyclohexylAla (Cha), Ile, Phe, Val or beta-(2-naphthyl)Ala (2-Nal), all modified with acyl (Ac)
	<220> <221> DOMAIN
25	<222> (2)..(8) <223> Cyclic
	<220> <221> MISC_FEATURE
30	<222> (4)..(4) <223> Xaa = D-Phe
	<220> <221> MISC_FEATURE
35	<222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
	<220> <221> MOD_RES
40	<222> (8)..(8) <223> AMIDATION
	<400> 33
45	Xaa Cys His Xaa Arg Trp Xaa Cys 1 5
	<210> 34 <211> 8 <212> PRT <213> Artificial Sequence
50	<220> <223> Melanocortin receptor ligand
	<220> <221> MISC_FEATURE
55	<222> (1)..(1)

5

<223> Xaa = Nle or Phe

<220>

<221> DOMAIN

<222> (2)..(8)

<223> Cyclic

10

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa = D-Phe

15

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa = 4-aminobutyric acid (Gaba)

20

<220>

<221> MOD_RES

<222> (8)..(8)

<223> AMIDATION

25

<400> 34

Xaa Cys His Xaa Arg Trp Xaa Cys

1 5

30

<210> 35

<211> 8

<212> PRT

<213> Artificial Sequence

35

<220>

<223> Melanocortin receptor ligand

40

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa = Nle modified with acyl (Ac)

45

<220>

<221> DOMAIN

<222> (2)..(8)

<223> Cyclic

50

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa = beta-(3-pyridiyl)Ala (3-Pal)

55

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa = D-Phe

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa = 4-aminobutyric acid (Gaba)

<220>

<221> MOD_RES

5<222> (8)..(8)

<223> AMIDATION

<400> 35

10

Xaa Cys Xaa Xaa Arg Trp Xaa Cys

1

5

15

<210> 36

<211> 8

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Melanocortin receptor ligand

<220>

25<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa = Nle modified with acyl (Ac)

<220>

30<221> DOMAIN

<222> (2)..(8)

<223> Cyclic

<220>

35<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa = D-Ala

<220>

40<221> MISC_FEATURE

<222> (5)..(5)

<223> Xaa = D-Phe

<220>

45<221> MOD_RES

<222> (8)..(8)

<223> C-terminus is the free acid

<400> 36

50

Xaa Cys Xaa His Xaa Arg Trp Cys

1

5

55

<210> 37

<211> 8

<212> PRT

<213> Artificial Sequence

<220>
<223> Melanocortin receptor ligand

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Nle modified with acyl (Ac)

<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa = D-Trp

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa = 4-aminobutyric acid (Gaba)

<220>
<221> MOD_RES
<222> (8)..(8)
<223> AMIDATION

<400> 37

Xaa Cys His Phe Arg Xaa Xaa Cys
1 5

<210> 38
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Melanocortin receptor ligand

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Nle modified with acyl (Ac)

<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)

<220>
<221> MISC_FEATURE

	<222> (7)..(7)	
	<223> Xaa = Ala or beta-Ala	
5	<220>	
	<221> MOD_RES	
	<222> (8)..(8)	
	<223> AMIDATION	
10	<400> 38	
	Xaa Asp His Xaa Arg Trp Xaa Lys	
	1 5	
15	<210> 39	
	<211> 8	
	<212> PRT	
	<213> Artificial Sequence	
20	<220>	
	<223> Melanocortin receptor ligand	
25	<220>	
	<221> MISC_FEATURE	
	<222> (1)..(1)	
	<223> Xaa = Nle modified with acyl (Ac)	
30	<220>	
	<221> DOMAIN	
	<222> (2)..(8)	
	<223> Cyclic	
35	<220>	
	<221> MISC_FEATURE	
	<222> (4)..(4)	
	<223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)	
40	<220>	
	<221> MISC_FEATURE	
	<222> (7)..(7)	
	<223> Xaa = 4-aminobutyric acid (Gaba) or 6-aminohexanoic acid (Ahx)	
45	<220>	
	<221> MOD_RES	
	<222> (8)..(8)	
	<223> AMIDATION	
	<400> 39	
50	Xaa Cys His Xaa Arg Trp Xaa Cys	
	1 5	
55	<210> 40	
	<211> 8	
	<212> PRT	
	<213> Artificial Sequence	
	<220>	
	<223> Melanocortin receptor ligand	

5

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = homo-Phe (hPhe) or beta-cyclohexylAla (Cha), both modified with acyl (Ac)

10

<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

15

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)

20

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa = 4-aminobutyric acid (Gaba)

25

<220>
<221> MOD_RES
<222> (8)..(8)
<223> AMIDATION

30

<400> 40

Xaa Asp His Xaa Arg Trp Xaa Lys
15

35

<210> 41
<211> 8
<212> PRT
<213> Artificial Sequence

40

<220>
<223> Melanocortin receptor ligand

45

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Nle modified with acyl (Ac)

50

<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

55

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = D-Phe

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa = beta-Ala or 5-aminopentanoic acid (Apn)

5

<220>
<221> MOD_RES
<222> (8)..(8)
<223> C-terminus is the free acid

<400> 41

10

Xaa Asp His Xaa Arg Trp Xaa Lys
1 5

<210> 42
<211> 8
<212> PRT
<213> Artificial Sequence

15

<220>
<223> Melanocortin receptor ligand

20

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Nle modified with acyl (Ac)

25

<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

30

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = D-Phe

35

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa = 6-aminohexanoic acid (Ahx) or 5-aminopentanoic acid (Apn)

40

<220>
<221> MOD_RES
<222> (8)..(8)
<223> C-terminus is the free acid

<400> 42

45

Xaa Cys His Xaa Arg Trp Xaa Cys
1 5

<210> 43
<211> 9
<212> PRT
<213> Artificial Sequence

50

<220>
<223> Melanocortin receptor ligand

55

<220>
<221> MISC_FEATURE

	<222> (1)..(1)
	<223> Xaa = D-Phe
5	<220> <221> DOMAIN <222> (2)..(9) <223> Cyclic
10	<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
15	<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = Ala, beta-Ala or 4-aminobutyric acid (Gaba)
20	<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
25	<220> <221> MOD_RES <222> (9)..(9) <223> C-terminus is the free acid
30	<400> 43 Xaa Cys His Xaa Arg Trp Xaa Xaa Thr 1 5
35	<210> 44 <211> 8 <212> PRT <213> Artificial Sequence
40	<220> <223> Melanocortin receptor ligand
45	<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = beta-cyclohexylAla (Cha), Nle, cyclohexylGly (Chg), D-beta-cyclohexylAla (D-Cha), homo-cyclohexylAla (hCha), D-cyclohexylGly (D-Chg) or homo-Phe (hPhe), all modified with acyl (Ac)
50	<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
55	<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe

	<220>	
	<221> MISC_FEATURE	
	<222> (7)..(7)	
5	<223> Xaa = 4-aminobutyric acid (Gaba)	
	<220>	
	<221> MOD_RES	
	<222> (8)..(8)	
10	<223> C-terminus is the free acid	
	<400> 44	
		Xaa Asp His Xaa Arg Trp Xaa Lys
15		1 5
	<210> 45	
	<211> 8	
	<212> PRT	
	<213> Artificial Sequence	
20	<220>	
	<223> Melanocortin receptor ligand	
	<220>	
25	<221> MISC_FEATURE	
	<222> (1)..(1)	
	<223> Xaa = Nle modified with acyl (Ac)	
	<220>	
30	<221> DOMAIN	
	<222> (2)..(8)	
	<223> Cyclic	
	<220>	
35	<221> MISC_FEATURE	
	<222> (4)..(4)	
	<223> Xaa = D-Phe	
	<220>	
40	<221> MISC_FEATURE	
	<222> (6)..(6)	
	<223> Xaa = D-Trp	
	<220>	
45	<221> MISC_FEATURE	
	<222> (7)..(7)	
	<223> Xaa = 4-aminobutyric acid (Gaba), 6-aminohexanoic acid (Ahx), beta-Ala or D-Ala	
	<220>	
50	<221> MOD_RES	
	<222> (8)..(8)	
	<223> C-terminus is the free acid	
	<400> 45	
55		Xaa Cys His Xaa Arg Xaa Xaa Cys
		1 5

5

<210> 46

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Melanocortin receptor ligand

10

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa = Nle modified with acyl (Ac)

15

<220>

<221> DOMAIN

<222> (2)..(8)

<223> Cyclic

20

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa = D-Ala

25

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)

30

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa = Trp, beta-(2-naphthyl)Ala (2-Nal), beta-(1-naphthyl)Ala (1-Nal) or 3-benzothienylalanine (Bal)

35

<220>

<221> MOD_RES

<222> (8)..(8)

<223> C-terminus is the free acid

40

<400> 46

Xaa Cys Xaa His Xaa Arg Xaa Cys

15

45

<210> 47

<211> 8

<212> PRT

<213> Artificial Sequence

50

<220>

<223> Melanocortin receptor ligand

55

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa = Nle modified with acyl (Ac)

<220>

<221> DOMAIN

	<222> (2)..(8)																
	<223> Cyclic																
5	<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = penicillamine (Pen)																
10	<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala																
15	<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe																
20	<220> <221> MOD_RES <222> (8)..(8) <223> C-terminus is the free acid																
25	<400> 47																
	<table><tr><td>Xaa</td><td>Xaa</td><td>Xaa</td><td>His</td><td>Xaa</td><td>Arg</td><td>Trp</td><td>Cys</td></tr><tr><td>1</td><td></td><td></td><td></td><td>5</td><td></td><td></td><td></td></tr></table>	Xaa	Xaa	Xaa	His	Xaa	Arg	Trp	Cys	1				5			
Xaa	Xaa	Xaa	His	Xaa	Arg	Trp	Cys										
1				5													
30	<210> 48 <211> 8 <212> PRT <213> Artificial Sequence																
35	<220> <223> Melanocortin receptor ligand																
40	<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)																
45	<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic																
50	<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe																
55	<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)																
	<220> <221> MISC_FEATURE																

<222> (8)..(8)
<223> Xaa = penicillamine (Pen)

5
<220>
<221> MOD_RES
<222> (8)..(8)
<223> C-terminus is the free acid

10
<400> 48

Xaa Cys His Xaa Arg Trp Xaa Xaa
1 5

15
<210> 49
<211> 8
<212> PRT
<213> Artificial Sequence

20
<220>
<223> Melanocortin receptor ligand

25
<220>
<221> MOD_RES
<222> (1)..(1)
<223> modified with acyl (Ac)

30
<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

35
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = D-Ala

40
<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)

45
<220>
<221> MOD_RES
<222> (8)..(8)
<223> AMIDATION

<400> 49

50
Arg Cys Xaa His Xaa Arg Trp Cys
1 5

55
<210> 50
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Melanocortin receptor ligand

[illegible]

	<220>								
	<221> MISC_FEATURE								
	<222> (8)..(8)								
5	<223> Xaa = penicillamine (Pen)								
	<220>								
	<221> MOD_RES								
	<222> (8)..(8)								
10	<223> AMIDATION								
	<400> 51								
		Xaa	Cys	Xaa	His	Xaa	Arg	Trp	Xaa
15		1				5			
	<210> 52								
	<211> 8								
	<212> PRT								
	<213> Artificial Sequence								
20									
	<220>								
	<223> Melanocortin receptor ligand								
	<220>								
25	<221> MISC_FEATURE								
	<222> (1)..(1)								
	<223> Xaa = D-Arg or Arg, both modified with acyl (Ac)								
	<220>								
30	<221> DOMAIN								
	<222> (2)..(8)								
	<223> Cyclic								
	<220>								
35	<221> MISC_FEATURE								
	<222> (4)..(4)								
	<223> Xaa = D-Phe								
	<220>								
40	<221> MISC_FEATURE								
	<222> (7)..(7)								
	<223> Xaa = 4-aminobutyric acid (Gaba)								
	<220>								
45	<221> MISC_FEATURE								
	<222> (8)..(8)								
	<223> Xaa = penicillamine (Pen)								
	<220>								
50	<221> MOD_RES								
	<222> (8)..(8)								
	<223> AMIDATION								
	<400> 52								
55		Xaa	Cys	His	Xaa	Arg	Trp	Xaa	Xaa
		1				5			

5

<210> 53

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Melanocortin receptor ligand

10

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa = D-Arg or Arg, both modified with acyl (Ac)

15

<220>

<221> DOMAIN

<222> (2)..(8)

<223> Cyclic

20

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa = D-Phe

25

<220>

<221> MOD_RES

<222> (8)..(8)

<223> AMIDATION

30

<400> 53

Xaa Asp His Xaa Arg Trp Ala Lys

15

35

<210> 54

<211> 9

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Melanocortin receptor ligand

45

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa = Nle modified with acyl (Ac)

50

<220>

<221> DOMAIN

<222> (2)..(9)

<223> Cyclic

55

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa = D-Ala

<220>

<221> MISC_FEATURE

<222> (5)..(5)
<223> Xaa = D-Phe

5
<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa = Gly, D-Ala, beta-Ala, 4-aminobutyric acid (Gaba) or 5-aminopentanoic acid (Apn)

10
<220>
<221> MOD_RES
<222> (9)..(9)
<223> AMIDATION

15
<400> 54

	Xaa	Cys	Xaa	His	Xaa	Arg	Trp	Xaa	Cys
	1				5				

20
<210> 55
<211> 8
<212> PRT
<213> Artificial Sequence

25
<220>
<223> Melanocortin receptor ligand

30
<220>
<221> MOD_RES
<222> (1)..(1)
<223> modified with acyl (Ac)

35
<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

40
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = D-Phe

45
<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa = Trp or beta-(2-naphthyl)alanine (2-Nal)

50
<220>
<221> MOD_RES
<222> (8)..(8)
<223> AMIDATION

<400> 55

	Cys	Glu	His	Xaa	Arg	Xaa	Ala	Cys
	1				5			

55
<210> 56
<211> 8

	<212> PRT	
	<213> Artificial Sequence	
	<220>	
5	<223> Melanocortin receptor ligand	
	<220>	
	<221> MOD_RES	
	<222> (1)..(1)	
10	<223> modified with acyl (Ac)	
	<220>	
	<221> DOMAIN	
	<222> (2)..(8)	
15	<223> Cyclic	
	<220>	
	<221> MISC_FEATURE	
	<222> (2).. (2)	
20	<223> Xaa = D-Ala	
	<220>	
	<221> MISC_FEATURE	
	<222> (4)..(4)	
25	<223> Xaa = D-Phe	
	<220>	
	<221> MISC_FEATURE	
	<222> (6)..(6)	
30	<223> Xaa = Trp or beta-(2-naphthyl)Ala (2-Nal)	
	<220>	
	<221> MOD_RES	
	<222> (8)..(8)	
35	<223> AMIDATION	
	<400> 56	
40	Cys Xaa His Xaa Arg Xaa Ala Cys	
	1 5	
	<210> 57	
	<211> 9	
	<212> PRT	
45	<213> Artificial Sequence	
	<220>	
	<223> Melanocortin receptor ligand	
50	<220>	
	<221> MISC_FEATURE	
	<222> (1)..(1)	
	<223> Xaa = Nle modified with acyl (Ac)	
55	<220>	
	<221> DOMAIN	
	<222> (2)..(9)	
	<223> Cyclic	

5

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = D-Ala

10

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = D-Phe

15

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa = Ala, beta-Ala or 4-aminobutyric acid (Gaba)

20

<220>
<221> MOD_RES
<222> (9)..(9)
<223> AMIDATION

25

<400> 57

Xaa Cys Xaa His Xaa Arg Trp Xaa Cys
1 5

30

<210> 58
<211> 9
<212> PRT
<213> Artificial Sequence

35

<220>
<223> Melanocortin receptor ligand

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Nle modified with acyl (Ac)

40

<220>
<221> DOMAIN
<222> (2)..(9)
<223> Cyclic

45

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = D-Ala

50

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = D-Phe

55

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa = 3-benzothienylAla (Bal)

5

<220>
<221> MOD_RES
<222> (9)..(9)
<223> AMIDATION

<400> 58

10

Xaa Asp Xaa His Xaa Arg Xaa Ala Lys
1 5

<210> 59
<211> 8
<212> PRT
<213> Artificial Sequence

15

<220>
<223> Melanocortin receptor ligand

20

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = D-homo-cyclohexylAla (D-hCha) modified with acyl (Ac)

25

<220>
<221> DOMAIN
<222> (2)..(8)
<223> Cyclic

30

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = D-Phe

35

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa = 4-aminobutyric acid (Gaba)

40

<220>
<221> MOD_RES
<222> (8)..(8)
<223> AMIDATION

<400> 59

45

Xaa Asp His Xaa Arg Trp Xaa Lys
1 5

50

<210> 60
<211> 8
<212> PRT
<213> Artificial Sequence

55

<220>
<223> Melanocortin receptor ligand

<220>
<221> MISC_FEATURE

	<222> (1)..(1)
	<223> Xaa = beta-cyclohexylAla (Cha) modified with n-butyryl
5	<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
10	<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
15	<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
20	<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
25	<400> 60
	Xaa Asp His Xaa Arg Trp Xaa Lys
30	15
35	<210> 61 <211> 8 <212> PRT <213> Artificial Sequence
40	<220> <223> Melanocortin receptor ligand
45	<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
50	<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
55	<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Glu
	<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe

```
<220>  
<221> MOD_RES  
<222> (8)..(8)  
<223> AMIDATION
```

5

<400> 61

Xaa Cys Xaa His Xaa Arg Trp Cys
1 5

10

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6613874 B [0009] [0010]
- US 6713487 B [0009]
- US 6600015 B [0009]
- US 6720324 B [0009]
- US 6639123 B [0009] [0010]
- US 6525019 B [0009]
- US 6350430 B [0009]
- WO 05060985 A [0009]
- US 5672659 A [0144]
- US 5595760 A [0144]
- US 5821221 A [0144]
- US 5916883 A [0144]
- US 60748850 B [0145]
- US 60697779 B [0145]

Non-patent literature cited in the description

- CONE et al. *Recent Prog. Horm. Res.*, 1996, vol. 51, 287-317 [0002]
- CONE et al. *Ann. N.Y. Acad. Sci.*, 1993, vol. 31, 342-363 [0002]
- TATRO, J. B. et al. *Endocrinol.*, 1987, vol. 121, 1900-1907 [0003]
- MOUNTJOY, K. G. et al. *Science*, 1992, vol. 257, 1248-1251 [0003]
- CHHAJLANI, V. et al. *FEBS Lett.*, 1992, vol. 309, 417-420 [0003]
- GANTZ, I. et al. *J. Biol. Chem.*, 1993, vol. 268, 8246-8250 [0003]
- GANTZ, I. et al. *J. Biol. Chem.*, 1993, vol. 268, 15174-15179 [0003]
- DE WIED, D. et al. *Methods Achiev. Exp. Pathol.*, 1991, vol. 15, 167-199 [0004]
- DE WIED, D. et al. *Physiol. Rev.*, 1982, vol. 62, 977-1059 [0004]
- GUBER, K.A. et al. *Am. J. Physiol.*, 1989, vol. 257, R681-R694 [0004]
- WALKER J.M. et al. *Science*, 1980, vol. 210, 1247-1249 [0004]
- MURPHY, M. T. et al. *Science*, 1983, vol. 221, 192-193 [0004]
- ELLERKMANN, E. et al. *Endocrinol.*, 1992, vol. 130, 133-138 [0004]
- VERSTEEG, D. H. G. et al. *Life Sci.*, 1986, vol. 38, 835-840 [0004]
- CONE, R. D. et al. *Ann. N.Y. Acad. Sci.*, 1993, vol. 680, 342-363 [0005]
- CONE, R. D. et al. *Recent Prog. Horm. Res.*, 1996, vol. 51, 287-318 [0005]
- GIRAUDO, S. Q. et al. *Brain Res.*, 1998, vol. 809, 302-306 [0008]
- FAROOQI, I. S. et al. *NE J Med.*, 2003, vol. 348, 1085-1095 [0008] [0009]
- MACNEIL, D. J. et al. *Eu. J. Pharm.*, 2002, vol. 44, 141-157 [0008] [0009]
- MACNEIL, D. J. et al. *Eu. J. Pharm.*, 2002, vol. 450, 93-109 [0008] [0009]
- KASK, A. et al. *NeuroReport*, 1999, vol. 10, 707-711 [0008] [0009]
- CATANIA, A. et al. *Pharm. Rev.*, 2004, vol. 56, 1-29 [0009]
- GETTING, S. J. et al. *Curr. Opin. Investig. Drugs*, 2001, vol. 2, 1064-1069 [0009]
- FEHM, H. L. et al. *J. Clin. Endo. & Metab.*, 2001, vol. 86, 1144-1148 [0009]
- HANSEN, M. J. et al. *Brain Res.*, 2005, vol. 1039, 137-145 [0009]
- YE, Z. et al. *Peptides*, 2005, vol. 26, 2017-2025 [0009]
- SCHWARTZ, M. W. *J. Clin. Invest.*, 2001, vol. 108, 963-964 [0009]
- GURA, T. *Science*, 2000, vol. 287, 1738-1740 [0009]
- RAFFIN-SANSON, M. L. *Eu. J. Endo.*, 2001, vol. 144, 207-208 [0009]
- HAMILTON, B. S. et al. *Obesity Res.*, 2002, vol. 10, 182-187 [0009]
- PONTILLO, J. et al. *Bioorganic & Med. Chem. Ltrs.*, 2005, vol. 15, 2541-2546 [0009]
- GE, Y. et al. *Brain Research*, 2002, vol. 957, 42-45 [0009]
- WISSE, B. R. et al. *Endo.*, 2001, vol. 142, 3292-3301 [0009]
- MARSILJE, T. H. et al. *Bioorg. Med. Chem. Lett.*, 2004, vol. 14, 3721-3725 [0009]
- MARKISON, S. et al. *Endocrinology*, 2005, vol. 146, 2766-2773 [0009]
- LECHAN, R. M. et al. *Endo.*, 2001, vol. 142, 3288-3291 [0009]
- STURM, R.A. *Melanoma Res.*, 2002, vol. 12, 405-416 [0009]
- BASTIENS, M. T. et al. *Am. J. Hum. Genet.*, 2001, vol. 68, 884-894 [0009]

- LUSCOMBE, C. J. et al. *British J. Cancer*, 2001, vol. 85, 1504-1509 [0009]
- VAN DER PLOEG, L. H. T. et al. *PNAS*, 2002, vol. 99, 11381-11386 [0009]
- MOLINOFF, P. B. et al. *Ann. N.Y. Acad. Sci.*, 2003, vol. 994, 96-102 [0009]
- HOPPS, C. V. et al. *BJU International*, 2003, vol. 92, 534-538 [0009]
- DIAMOND, L. E. et al. *Urology*, 2005, vol. 65, 755-759 [0009]
- WESSELLS, H. et al. *Int. J. Impotence Res.*, 2000, vol. 12, S74-S79 [0009]
- ANDERSSON K-E. et al. *Int. J. Impotence Res.*, 2002, vol. 14, S82-S92 [0009]
- BERTOLINI, A. Sexual Behavior: Pharmacology and Biochemistry. Raven Press, 1975, 247-257 [0009]
- WESSELLS, H. et al. *Neuroscience*, 2003, vol. 118, 755-762 [0009]
- WESSELLS, H. et al. *Urology*, 2000, vol. 56, 641-646 [0009]
- SHADIACK, A. M. et al. *Society for Neuroscience Abstract*, 2003 [0009]
- WESSELLS, H. et al. *J. Urology*, 1998, vol. 160, 389-393 [0009]
- ROSEN, R. C. et al. *Int. J. Impotence Res.*, 2004, vol. 16, 135-142 [0009]
- WESSELLS, H. et al. *Peptides*, 2005, vol. 26, 1972-1977 [0009]
- FOURCROY, J. L. *Drugs*, 2003, vol. 63, 1445-1457 [0009]
- MIONI, C. et al. *Eu. J. Pharm.*, 2003, vol. 477, 227-234 [0009]
- SHARMA H. S. et al. *Acta. Neurochir.*, 2003, vol. 86, 399-405 [0009]
- SHARMA H.S. *Ann. N.Y. Acad. Sci.*, 2005, vol. 1053, 407-421 [0009]
- HARRIS, R. B. et al. *Physiol. Behav.*, 2001, vol. 73, 599-608 [0009]
- LUGER, T. A. et al. *Pathobiology*, 1999, vol. 67, 318-321 [0009]
- HATTA, N. et al. *J. Invest. Dermatol.*, 2001, vol. 116, 564-570 [0009]
- BOHM, M. et al. *J. Invest. Dermatol.*, 2002, vol. 118, 533-539 [0009]
- CHAKI, S. et al. *Peptides*, 2005, vol. 26, 1952-1964 [0009]
- BEDNAREK, M. A. et al. *Expert Opinion Ther. Patents*, 2004, vol. 14, 327-336 [0009]
- VOISEY, J. et al. *Curr. Drug Targets*, 2003, vol. 4, 586-597 [0009]
- BERTOLINI, A. et al. *J. Endocrinol. Invest.*, 1981, vol. 4, 241-251 [0009]
- VRINTEN, D. et al. *J. Neuroscience*, 2000, vol. 20, 8131-8137 [0009]
- NAVARRO, M. et al. *Alcohol Clin. Exp. Res.*, 2005, vol. 29, 949-957 [0009]
- DUMONT, L. M. et al. *Peptides*, 2005, vol. 26, 1929-1935 [0010]
- STEWART, J.M. et al. Solid Phase Synthesis. Pierce Chemical Co, 1984 [0107]
- SCHNOLZER et al. *Int. J. Peptide Protein Res.*, 1992, vol. 40, 180 [0113]

Patentkrav

1. Forbindelse, der er Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂ (SEQ ID NO: 50) eller et farmaceutisk acceptabelt salt deraf, eller en farmaceutisk sammensætning
5 omfattende en terapeutisk virksom mængde af forbindelsen og en farmaceutisk acceptabel bærer eller fortynder, til anvendelse i terapi.
2. Forbindelse eller farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor
10 terapien er behandling af et pattedyr.
3. Forbindelse eller farmaceutisk sammensætning til anvendelse ifølge krav 2, hvor
pattedyret er et menneske.
4. Anvendelse af en forbindelse til fremstilling af et lægemiddel til behandling af en
15 stofskiftesygdom eller medicinsk tilstand ledsaget af vægtstigning, hvor sygdommen eller tilstanden er udvalgt fra gruppen bestående af fedme, spiseforstyrrelser og Prader-Willis syndrom, og hvor forbindelsen er Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂ (SEQ ID NO: 50) eller et farmaceutisk acceptabelt salt deraf.
- 20 5. Anvendelse ifølge krav 4, hvor sygdommen eller tilstanden fedme eller en spiseforstyrrelse.
6. Anvendelse ifølge krav 4, hvor sygdommen eller tilstanden er Prader-Willis syndrom.

DRAWINGS

Figure 1A




Figure 1B




Figure 2B




Figure 3A




Figure 3B




Figure 4A




Figure 4B

